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Nanoparticles are spherical aggregates less than 100nm in diameter containing a few 
hundreds to thousands of atoms. Fluorescent nanoparticles excited by near infrared 
(NIR) are advantageous because NIR gives rise to minimal autofluorescence which 
results in very high signal-to-background ratios; cells and tissue destruction is low 
because NIR is harmless to biomolecules in low doses; and nanoparticles can be 
imaged from inside tissues because of deep penetration of NIR radiation. This thesis 
explores the characterization and biomedical applications of a new variety of NIR 
excited fluorescent nanoparticles, PEI/NaYF44:Er,Yb, developed at the Cellular and 
Molecular Bioengineering Laboratory, with a focus on cancer.  
PEI/NaYF4 upconversion nanoparticles co-doped with Er and Yb were demonstrated 
to be 60 nm spherical particles of uniform shape and size, positive surface charge and 
stably soluble in de-ionized water. When excited with 980nm laser these emitted light 
with sharp peaks in the red and green region of the visible spectrum.  This emission 
was strongly photostable and immune to storage over weeks, although incubation in 
serum at physiological temperatures slowly degraded the signal, probably by protein 
deposition.  The particles were biocompatible with two different human cell lines to 
moderately high concentrations and for reasonable periods of incubation.  
 
The upconverting nanoparticles (UCN) were conjugated to a cell-specific ligand and 
used for targeted imaging of live human cancer cells in vitro. These showed strong 
signal-to-background ratios and high sensitivity of detection. Non-targeted tagging of 
cells using PEI polymer as a positively charged coupler was also demonstrated. All 






prolonged laser exposure. The ability to image these nanoparticles inside animals was 
demonstrated by injecting into various tissues of live, anaesthetized rats and exciting 
the injection site with NIR laser. Fluorescence from injected nanoparticles was 
recorded at injection depths of a few millimeters to nearly 1 cm, the depth depending 
on the type of tissue injected, the dose of nanoparticles and the effective control of 
ambient light which contributes to background. Human cancer cells, non-specifically 
tagged with upconversion nanoparticles, were injected subcutaneously in live 
anaesthetized mice and the cells imaged by real-time in vivo confocal microscopy.  
 
Photodynamic therapy (PDT) is a therapeutic option for cancer that relies on the 
interaction of light and photosensitizer drugs to kill targeted cells. Acceptance of PDT 
has been limited by, among other factors, fear of high cost of setup and inability to 
easily reach deeper seated tumors. We demonstrated a nanoparticle-based approach to 
address these problems. UCN were functionalized with zinc phthalocyanine (ZnPC) 
photosensitizer for simultaneous imaging and photodynamic therapy. The 
nanoparticles act as ‘nano-transducers’ to convert deeply tissue penetrating NIR 
excitation to emission frequencies suitable to activate the photosensitizer to release 
reactive oxygen species to kill cancer cells. The effectiveness of the modified 
nanoparticles for this purpose was demonstrated in vitro with concurrent imaging.  
 
Both the imaging and photodynamic therapy of cancer cells using PEI/NaYF44:Er,Yb 
nanoparticles were described, to the best of my knowledge, for the first time, although 
several preliminary results using large phosphor ‘nanoparticles’ in excess of 100nm in 
diameter can be found in the literature. These results lead the slow emergence of the 






to rival more established labels in sensitivity and safety, especially for long term live 
imaging of cellular processes. The application in photodynamic therapy demonstrates 
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1.1 Definition and scope 
 
Nanoparticles can be defined as spherical particles, with at least one dimension less 
than 100nm (Leuschner et al., 2005). Nanoparticles were probably first introduced by 
Birrenbach and Speiser (Birrenbach et al., 1976). The first nanoparticulate 
formulations were made by emulsion polymerizations. Methods were later developed 
(like phase separation, controlled gelation etc) that made use of preformed polymers 
with already characterized physicochemical properties. This allowed better control 
over the nanoparticles' properties. Nanoparticles along with liposomes and block co-
polymer micelles form the group of submicron size colloidal systems used for 
targeted drug delivery. Nanoparticles with intended clinical use should be less than 
100nm in diameter (Brigger et al., 2002). This small size allows intravenous 
administration without the risk of embolization, passage through capillary vessels 
(Courvreur P, 1986) and mucosa (Florence et al., 2001), large surface area, significant 
surface properties and greater solubility (especially for oil based drugs) (Kawashima, 
2001).  
 
Several recent reviews have explored biomedical applications of nanoparticles. Ferrari 
(Ferrari, 2005) has dealt with the whole field of cancer nanotechnology, including the 
in vitro diagnostics as well as in vivo targeting, while Jain has focused on drug 
delivery in cancer (Jain, 2005). Others have discussed nanotechnology for the 
biologist (McNeil, 2005) and its uses to the whole field of molecular recognition, 
mainly for enhanced in vitro molecular diagnostics (Fortina et al., 2005). We have 
elsewhere reviewed use of nano-vectors in cancer (Zhang et al., 2006). The following 






1.2 Nanoparticles for disease diagnostics 
 
Nanoparticles can be used in diagnosis and therapy of diseases in several ways. The 
major benefit of using nanoparticles is that these allow a common platform to 
combine two or more independent functions (Figure 1-1).  Targeting is an important 
and ubiquitous function which allows concentration of the nanoparticles in defined 
areas. Diagnostic benefits are mainly derived from luminescent and ferromagnetic 
nanoparticles which can be used for detection and monitoring of diseased tissues. 
Therapeutically, drug-loaded nanoparticles can achieve high local concentration of the 
toxic drug while reducing circulating levels of free drug, thus lowering systemic 
toxicity (Leuschner et al., 2005).  
 
 
Figure 1-1 Different roles of nanoparticles for biomedical applications 
 
The following sections deal with each of the three functions separately with specific 
reference to application in cancer diagnosis and management. Description of methods 
of targeting and concentrating nanoparticles in tumors is followed by sections which 







1.2.1 Molecular targeting using nanoparticles 
 
Definition: Targeting can be loosely defined in this context as any means that 
increases the specificity of localization of nanoparticles to diseased cells. Targeting 
does not intrinsically imply improved sensitivity, but the different methods employed 
to increase the specificity allows administration of higher doses of the drugs, thus also 
favorably increasing sensitivity. Also, as mentioned earlier, the ability of nanoparticles 
to cross blood brain barrier and other impediments to conventional therapy increases 
its volume of distribution. This also results in increased sensitivity.  
 
Targeting can be divided into two major types – passive and active. It must be noted 
that any of these methods can used in conjunction with others. For example, common 
mechanisms for passive targeting like PEGylation is frequently used with more active 
targeting ligands like antibodies. The methods are almost independent of each other, 
and can be judiciously combined to increase effectiveness of the drugs. As noted 
above, the following discussions relate specifically to tumors.  
 
Passive targeting involves modifications of nanoparticles which increase circulation 
time without addition of any component/involvement of any method which is specific 
to the tumor. Increased circulation time helps in accumulation of the particles in the 
tumor by an enhanced permeation and retention, or EPR, effect. Long circulating 
nanoparticles show a preferential distribution to cancer sites over healthy tissues, even 
without any specific targeting molecule. This is probably due to the increased 
vasculature of these regions, larger fenestrations in the capillary walls for rapid 






neoplastic process; and the reduced lymphatic drainage in these regions. All these 
factors lead to a sieve-like effect for nanoparticles in tumors (Sledge et al., 2003; 




Figure 1-2 Tumor targeting with nanoparticles by passive and active targeting 
 
Stealth nanoparticles: Nanoparticles in circulation are usually marked as foreign and 
rapidly removed by the reticulo-endothelial system (RES) or mononuclear phagocyte 
system (MPS) in the liver and spleen before sufficient amounts accumulate in tumors. 
Hence, a lot of research has been directed to create nanoparticles that have reduced 
rates of removal by the RES. Usually this takes the form of special polymer coatings 






nanoparticles. For example, attachment of poly(ethylene glycol) (PEG) ‘hides’ 
nanoparticles from the MPS enabling longer circulation times. Longer time in 
circulation increases the probability of the nanoparticles being trapped in tumors by 
EPS. In fact, it has been shown that PEG-coated poly(cyanoacrylate)(pCA) 
nanoparticles - made by a copolymer inculcating both – has such a long circulating 
time that they penetrated the brain more than any other modifications, including 
coating by polysorbate. This uptake was increased in pathological situations with 
presumably higher blood-brain barrier permeability. Another example is the 
incorporation of cisplatin in liposomal formulations (Chawla et al., 2002) with PEG 
coating for gastric tumors: in preclinical and clinical trials, this formulation has been 
demonstrated to have longer half life in circulation without the attendant side effects. 
Poloxamine and poly(ethylene oxide) have been proposed as alternatives to PEG for 
producing steric stabilization. In a study (Shenoy et al., 2005) tamoxifen was 
encapsulated in poly(ethylene oxide) – modified poly(varepsilon-caprolactone) (PEO-
PCL) nanoparticles and administered to a murine model of breast cancer. The 
poly(ethylene oxide) coating made it a ‘stealth nanoparticle’: able to avoid detection 
by the body’s MPS system for a considerable amount of time. The PEO surface 
modified nanoparticles showed significantly increased level of accumulation within 
the tumor with time as compared to the native drug or surface unmodified 
nanoparticles.  
 
Active targeting involves the modification of nanoparticles’ surfaces with ligands 
which are tumor-specific. Cancer cells arise from normal cells through a complex 
series of genetic events. Unlike infectious agents like bacteria, they largely share the 






mutated forms of normal proteins are found exclusively on cancer cells. These are 
known as Tumor Specific Antigens (TSA). The obvious targets for targeted cancer 
therapy are TSAs. However, TSAs are often difficult to characterize for a particular 
tumor. When found, they are usually not extensive, i.e. they are not found in all 
patients affected by the tumor, nor are they found in all the cells in a particular tumor 
in the same patient. The tumor specific antigens are produced by aberrant 
glycosylation in glycolipids, glycoproteins, proteoglycans, and mucin (Hakomori, 
1992). Examples include MUC1 membrane mucin of breast cancer epithelial cells 
which differs from normal breast epithelial cells in the glycosylation pattern, possibly 
as a result of changes in expression of glycosyltranferases (Taylor-Papadimitriou et al., 
1999), TAG-72 mucin like tumor-associated glycoprotein (Colcher et al., 1991) that is 
found in some epithelial tumors, aberrantly expressed GM3 ganglioside on the surface 
of melanoma cells (Hirabayashi et al., 1985), and abnormally expressed LeX antigens 
on gastrointestinal cancer cells (Hakomori, 1996). 
 
Some natural proteins are found in much larger numbers on cancer cells than in 
normal cells (Browning, 1995). These over-expressed antigens are called Tumor 
Associated Antigens (TAA). Tumor associated antigens are often growth factor 
receptors on the tumor that are over-expressed to meet the rapidly dividing neoplastic 
cells’ demands. For example, presence of elevated levels of folate receptors have been 
demonstrated from epithelial tumors of various organs such as the colon, lungs, 
prostate, ovaries, mammary glands, and brain. (Coney et al., 1991; Garin-Chesa et al., 
1993; Hattori et al., 2004; Holm et al., 1991; Mattes et al., 1990; Oyewumi et al., 
2004; Quintana et al., 2002; Ross et al., 1994; Toffoli et al., 1997; Weitman et al., 






is a transmembrane epidermal growth factor receptor which possesses intrinsic 
tyrosine kinase activity (Bargmann et al., 1986; Coussens et al., 1985; Yamamoto et 
al., 1986). Over-expression of the normal human Her-2_neu proto-oncogene is 
frequently found in breast and ovarian cancers among others. Its level may correlate 
with the metastatic potential of the cancer cells (Borg et al., 1990; Slamon et al., 
1987). The transferrin receptor is found to be over-expressed in different types of 
cancers (Keer et al., 1990). Their levels may also correlate with the malignant 
potential of these cells. Presence of various other tumor antigens has been 
demonstrated: membrane associated Carcinoembryonic antigen; CD10 or CALLA in 
leukemias, melanomas and myelomas (Carrel et al., 1993; LeBien et al., 1989); CD20 
in B cell malignancies (Vervoordeldonk et al., 1994); etc. Many others are being 
recognized routinely. All represent potential goals for targeted drug delivery. 
 
Targeting can be enhanced or achieved by other factors too. One of these is the use of 
drugs that act preferentially on tumor cells. While most conventional 
chemotherapeutic drugs now in use have greater or lesser degrees of tumor selectivity 
(usually by targeting the rapid proliferation of tumor cells), greater selectivity may be 
achieved by using siRNA that are specific for tumor antigens (described in detail 
later). Another type of targeting demonstrated by Potineni, et al (Potineni et al., 2003) 
describes a method to utilize pH differences to release drugs at tumor sites. They 
demonstrated the in vitro release of the anticancer drug paclitaxel by biodegradable 
Poly(ethylene oxide)-modified poly( -amino ester) nanoparticles. This can 
theoretically be reproduced at cancer sites, which have high metabolic rates and 
altered pH. Physical targeting can be achieved by directing magnetic nanoparticles to 






1.2.2 Fluorescent nanoparticles as imaging probes 
 
Fluorescent nanoparticulate probes in biological imaging have enjoyed a huge growth 
in recent years (Medintz et al., 2005; Michalet et al., 2005; Wang et al., 2006). 
Reporter technologies have uses in qualitative as well as quantitative analyses. 
Fluorescent reporters can broadly be classified into organic molecules and 
nanoparticles.  Two major varieties of fluorescent nanoparticles discussed here are 
quantum dots and phosphor nanoparticles.  
 
Organic fluorophores have the advantage of small size, allowing the multivalent 
attachment of fluorescent labels to each target molecule. This enhances the 
fluorescence detection efficiency. Moreover, the organic molecules are usually bio-
compatible and can be used in most biological assays. However, the organic 
molecules often lack adequate stability and photobleach easily on continued 
irradiation. Thus while they are useful for optical imaging of fixed biological cells and 
tissues and for studies like immunochromatography, their value for continuous 
imaging is limited. A second problem is the presence of other organic molecules (like 
collagen and laminin) in biological tissues which also show variable degrees of 
fluorescence (‘autofluorescence’). This creates a high background for imaging and 
reduces the signal-to-noise ratio and thus the lower limit of detection. Thirdly, active 
targeting is difficult because covalent conjugation with target molecules causes 
unpredictable changes in the molecular structure of the organic fluorophore resulting 








Quantum dots (QDs) are nanoparticles of one semiconductor encased in a second 
semiconductor. These can be of considerable use as inorganic fluorophores, because 
they offer significant advantages over organic fluorescent labels. These exhibit strong 
fluorescence emission, a broad absorption spectra and a narrow, symmetric emission 
spectrum, and are photochemically stable. QDs also exhibit a wide range of colors 
which is exquisitely controlled by their size, and a broad absorption spectra means 
that a series of different-colored dots can be activated using a single laser. These are 
small (usually 4-5 nm in diameter) and are much more photostable than organic 
molecules and can be used for long term imaging of cellular processes without 
appreciable reduction in fluorescent intensity. Cell-specific ligand molecules can be 
attached to QDs for active targeting. Covalent attachment of these molecules usually 
does not alter the fluorescent efficiency of the QDs because the process of quantum 
confinement of electrons that is responsible for the fluorescence is independent of 
environmental influence. 
 
Successful examples of QDs include the coating of QDs with a polyacrylate cap and 
covalently linking them to antibodies or to streptavidin for use in labeling surface, 
cytoskeletal and nuclear proteins in fixed cells and tissue sections  (Wu et al., 2003). 
Labeling was highly specific, and was brighter and more stable than that of other 
fluorescent markers. Moreover, the authors simultaneously used two QDs of different 
emission spectra and managed to detect two different targets with a single excitation 
wavelength. Wu et al. also succeeded in labeling live cells with their QDs, but in a 
second paper, Jaiswal et al. (Jaiswal et al., 2003) provide more compelling evidence 
for the use of QDs in vivo. The authors coated the nanoparticles with dihydrolipoic 






intermediate, positively charged protein. The authors allowed cells to incorporate the 
QDs by endocytosis and followed their fate for more than a week. The cells continued 
to grow, differentiate and respond to cellular signals in a normal way. Similarly, the 
label was stable throughout the experiment and there was minimal nonspecific 
binding. Last, Jaiswal et al. also used QDs with different emission properties to show 
the feasibility of simultaneously detecting more than one fluorophore. 
 
Despite their promise, QDs face several problems for use as biological probes. Firstly, 
QDs are made from non-polar constituents and require modification of their surface 
for use in physiological media and attaching ligand molecules. Secondly, QDs have a 
problem with possible toxicity from the constituent highly toxic semiconductor 
elements. There have been several reports that demonstrate that the toxicity of these 
particles are minimal, especially after surface modification with organic molecules, 
but more experience is needed before clinical use can be unconditionally approved. 
Thirdly, QDs require UV or short wavelength light for excitation. These have very 
limited penetration into tissues because of scattering and absorption of optical photons. 
Fourth, similar to organic labels, under UV or VIS excitation biological samples show 
strong autofluorescence from chromophores like collagens and porphyrins, which 
decreases the sensitivity of detection (Konig, 2000; Kuningas et al., 2005). Fifth, if 
the semiconductors are not perfectly coated, the fluorescent signal is liable to be 
quenched. Finally, UV radiation has potential carcinogenic and cytotoxic effects, and 
is therefore not an attractive option for live cell/tissue imaging. Therefore, in recent 
years there has been an increasing interest in phosphor nanoparticles which can avoid 







Upconverting phosphor nanoparticles are low energy activated nanoparticles that 
emit visible phosphorescence by an ‘upconversion’ process.  In common with QDs, 
these reporters are chemically stable, resistant to photobleaching, have narrow 
emission bands, exhibit fluorescence that is independent of environmental effects and 
can be targeted to specific biomolecules by conjugating ligands on surface. In 
common with organic fluorophores, they have low toxicity to biological cells and 
tissues because the rare earth elements at the heart of the particles are generally 
biocompatible (the half-maximal lethal dose - LD50 – of rare earth elements is 
approximately a thousand times more than that of semiconductor elements of 
quantum dots (Palmer et al., 1987)) In addition, they possess the unique property of 
infrared up-conversion, and are readily detected because of the lack of 
autofluorescence in the background (Table 1-1).  
 
One of the major drawbacks is that the reported synthetic procedures result in large 
and highly non-uniform sized particles, usually measuring several hundred 
nanometers. Moreover, coating with organic polymers or a silica shell (usually 
necessary to make the particles soluble in physiological solvents) increases the 
diameter of the particles. The silica shell alone can increase the diameter of the 
particles by 5-50nm. It is generally accepted that in vivo use of nanoparticles with 
free transfer through endothelial barriers would require diameter sizes of 100nm or 
less. Hence the reported phosphor particles have been overwhelmingly used for in 
vitro assays. Even for in vitro assays the relatively large size of the probes (in excess 
of 350nm as compared to less than 5 nm for most organic fluorescent probes) was a 
disadvantage. Other concerns related to the use of large sized particle reporter 






dynamic range of labeling. In vitro results however, indicate that these theoretical 
disadvantages do not often play an important role.(Frangioni, 2003) One of the 
biggest hurdles to quantitative analysis is the batch to batch variability in emission 
efficiency of nanoparticles. This limits the comparative value of quantitative results 
across batches and must be addressed by better production techniques. This variability 
can be minimized by better synthetic processes, or by better post-manufacturing 
separation of particles by size so that only particles within a small size range are used 
for analysis, or by control or calibration measures with adjusted test results. Another 
hurdle is the absence of commercial readers for assay analysis. Most fluorescence 
based assays use UV excitation and visible emission detection, and are not suitable for 
NIR use. Laboratory studies make do with local setups but this makes comparison of 
results difficult. Similarly, absence of an upconverting ‘standard’ for comparison 
makes studies of quantum yield difficult.  
 
Since emission is dependent on the number of ions available for transfer of photons 
and subsequent emission, emission efficiency is generally dependent on particle size. 
Increased emission can be obtained by either increasing concentration of particles, or 
by using larger particles or by using higher power of incident radiation. The process 
of upconversion does not necessarily require coherent light, but a focused laser beam 
is often used in order to obtain high emission efficiency. The remarkable 
photostability of the particles allows the use of laser for relatively long periods 
without significant bleaching. However, higher powers of the NIR laser can cause 
thermal damage to biological tissues especially if used for long periods. A balance 
between emission efficiency and tissue safety has to be obtained for optimum imaging 






synthesized, there will be an obvious limit to the size of the nanoparticles that can be 
fruitfully used as biological probes. Too small particles may not provide enough 
conversion efficiency for efficient detection. 
 
One of the earliest examples demonstrating the biomedical use of phosphor particles 
dealt with their use in immunohistochemistry.(Zijlmans et al., 1999) Subsequently, the 
design of lateral flow (LF) assay formats that utilize phosphors to interrogate test 
strips for drugs of abuse and bacterial antigens (Niedbala et al., 2001) or for 
immunochromatographic assays for human chorionic gonadotropin (hCG) (Hampl et 
al., 2001) were described. A host of in vitro nucleic acid assays have also been 
described. (Corstjens et al., 2001; Corstjens et al., 2003; van de Rijke et al., 2001; 
Wang et al., 2006; Zhang et al., 2006)  The reported in vitro assays - both for proteins 
and DNA sequences - have shown promise with high detection sensitivity of the target 
molecules. These assays have mostly utilized the property of NIR light to excite 
minimal autofluorescence from other bio-molecules. In addition, a recent assay has 
used the unique absorption-emission profile of phosphor particles to couple them with 
conventional fluorophores with suitably matching profiles to create a single chamber 
assay that demonstrates unique fluorescence emission from NIR excitation in the 













Quantum Dots Phosphor 
nanoparticles 
Size < 5 nm 4-8 nm* 50 – 250 nm 
Resistance to 
photobleaching 
+ +++ +++ 
Dark toxicity + +++* ++ 
Excitation/Emission UV/Vis UV/Vis, NIR/IR NIR/Vis 
Excitation 
radiation toxicity 
+++ +++ /+ + 
Autofluorescence +++ +++/+ - 
Immunity to 
environment 
+ +++ +++ 
Brightness +++ +++ ++ 
Targeting ligand 
can be attached 
No Yes Yes 
Cost of equipment + +/+++ ++ 
Use in vivo in 
mammals 




Yes, especially for 
NIR/IR QDs 
None previously 






1.3 Nanoparticles in therapeutic applications  
 
The primary therapeutic application for nanoparticles is drug delivery. However, 
several other approaches have been explored: particularly in thermal ablation therapy 
and photodynamic therapy of tumors. 
 
1.3.1 General principles 
 
Nanoparticles as vehicles of targeted drug delivery enjoy several advantages. Drug-
loaded nanoparticles can target diseased sites and achieve high local concentration of 
the toxic drug while reducing circulating levels of free drug, thus reducing systemic 
toxicity. Secondly, attachment to nanoparticle surface increases the stability of 
molecules. This is particularly important in the case of peptides, nucleic acids (like 
anti-HA-ras (Schwab et al., 1994) and anti-Ewing sarcoma (Lambert et al., 2000) ) 
and small proteins (like antibodies), which are easily removed from the circulation in 
the free form. Thirdly, it is also important for carrying poorly soluble drugs (e.g. 
muramyl tripeptide cholesterol (Morin et al., 1994) ) in significant quantities without 
the usual side effects. While antibody conjugated therapies can only deliver single 
molecules of drug per recognition event, nanovectors can deposit a much larger 
amount. This makes nanoparticles particularly attractive while dealing with toxic 
drugs. They can increase circulatory period of drugs by controlled release, thus 
overcoming the toxicity associated with initial high concentration in periodic doses 
(Leuschner et al., 2005). Finally, nanoparticles can enter regions of the body 
inaccessible to soluble drugs (‘tumor sanctuaries’) to treat previously untreatable 






attributed to cell nests in the CNS because intravenous drug formulations fail to cross 
the blood brain barrier. Nanoparticles have been demonstrated to be able to 
accomplish this feat, perhaps by trans-cellular movement after endocytosis by the 
endothelial cells. Some examples of this include the use of polysorbate 80-coated 
nanospheres to deliver Kytorphin, tubocurarine and doxorubicin to the brain. 
Polysorbate 80 adsorbs apolipoprotein E from the circulation and become attached to 
the low-density lipoprotein receptors on the endothelial surface. 
 
A drawback of this method of delivery is the issue of process control enabling 
appropriate encapsulation and release of the drug. Especially with the synthetic 
methods derived from microencapsulation techniques, there may be considerable 
difficulty in encapsulating the drug and then controlling its release after encapsulation. 
A theoretical drawback has been predicted by modeling of the nanoparticle delivery 
called ‘diffusional instability’. Vittorio Cristini et al (Sinek et al., 2004) have shown 
that the delivery of cytotoxic agents to tumors, particularly anti-angiogenic drugs, 
might fractionate the lesion into multiple satellite neoplasms. This is likely due to the 
rearrangement of the sources of oxygen and nutrient supply because of the anti-
angiogenic therapy.  
 
The major mechanisms of action of nanoparticles can be divided into physical, 
chemical or biological means. Physical means include the recently developed methods 
of hyperthermia and magnetic therapy. Chemical means include the delivery of the 
more conventional chemotherapeutic drugs to the tumor sites. Biological response 
modifiers like immunotherapeutic agents are also gaining favor. Further discussions 






the points made hold true for gene delivery/immunotherapeutic agents.  
 
A nanoparticle designed for targeted delivery of anticancer agents will have three 
components: a) the capsule or matrix or core that provides the platform to bind or 
contain: b) the drug or anticancer agent, and c) the targeting molecule. This whole 
arrangement can be protected from the attacks of the immune system by steric 
stabilization; usually by the attachment of PEG to the surface. These modified 
nanoparticles have been labeled ‘nanovectors’ (Ferrari, 2005) as an indication of their 
function as carriers of large therapeutic payloads to target sites.  
 
In the described tripartite arrangement, an optimum combination of matrix, drug and 
targeting element is required. A large number of matrix polymers have been tested for 
their drug uptake and surface modification abilities (Duncan, 2003). The role of the 
surface modified matrix and the targeting molecule is to effectively deliver the drug to 
the target site. For this, they must provide stability to peptides and others drugs with 
short half lives in circulation; avoid uptake by the MPS or RES; circumvent the 
endothelial and blood-brain barrier; be non-toxic to normal body tissues; and finally 
deliver the drug to the tumor cells, avoiding the enhanced osmotic pressure in tumor 
regions (Netti et al., 1995) and ensuring uptake and action. In addition, the matrix 
may be composed of specialized material that fluoresces on excitation and converts 







1.3.2 Nanoparticles for photodynamic therapy of cancer 
 
As briefly noted earlier, nanoparticles can be used for cancer therapy, primarily as a 
drug delivery vehicle. In this thesis, we have proposed the use of upconverting 
nanoparticles for photodynamic therapy (PDT) of cancer. This section provides a brief 
introduction for this therapeutic modality. 
 
1.3.2.1 Principles of photodynamic therapy 
 
Photodynamic therapy (PDT) is an emerging, promising modality for the treatment of 
a variety of oncological, cardiovascular, dermatological and ophthalmic diseases; one 
of its main therapeutic applications is in cancer therapy. Currently, PDT is used 
against bladder, esophageal, gastric, brain, breast, skin, colorectal, oral, head and neck 
cancers, in addition to gynaecological and thoracic malignancies. 
 
The mechanism of PDT is based on the concept that light-sensitive species or 
photosensitizers can be preferentially localized in tumour tissues upon systemic 
administration. Irradiation of such photosensitizers with an appropriate wavelength of 
visible or near-infrared light causes the excited molecules to transfer their energy to 
molecular oxygen in the surroundings, which is normally in its triplet ground state. 
This results in the formation of cytotoxic reactive oxygen species, such as singlet 
oxygen or free radicals, which are responsible for oxidizing various cellular 
compartments including plasma, mitochondria, lysosomal and nuclear membranes, 






by necrosis and apoptosis both in vivo and in vitro, but the factors determining the 
contribution of either mechanism to the overall process are not completely defined. 
Besides tumour cells, the targets of PDT also include the microvasculature of the 




Figure 1-3 Principle of photodynamic therapy 
 
Compared to current treatments such as surgery, radiation therapy and chemotherapy, 
PDT offers the advantages of an effective and selective method (since 
photosensitizers are inactive without light activation, PDT can ideally be considered 
to be selective to the illuminated area) of destroying diseased tissues without 
damaging surrounding healthy tissues, a type of treatment where repeated doses can 
be given without the total-dose limitations associated with radiotherapy and where the 
healing process results in little or no scarring. In addition, in contrast to most other 
cancer therapies, PDT can induce immunity, even against less immunogenic tumours, 






Despite PDT’s advantages over current treatments, PDT has yet to gain general 
clinical acceptance because of certain disadvantages. Currently approved PDT 
photosensitizers absorb in the visible spectral regions below 700 nm, where light 
penetration into the skin is only a few millimeters, clinically limiting PDT to treating 
topical lesions. Most tissue chromophores, including oxyhemoglobin, 
deoxyhemoglobin, melanin and fat, absorb weakly in the near infrared (NIR) spectral 
range (700 – 1100 nm) - the wavelengths where the deepest penetration of light can be 
achieved, but most photosensitizers have absorption bands at wavelengths shorter 
than 800 nm.  
 
1.3.2.2 Factors that contribute to the effectiveness of PDT 
 
The effectiveness of PDT is largely determined by the efficiency of singlet oxygen 
production and the degree of efficiency and selectivity to which therapeutic 
concentrations of the photosensitizer is delivered to the target site with minute uptake 
by non-target cells. 
 
Efficiency of singlet oxygen production: Many factors influence how efficiently 
singlet oxygen is generated in a PDT process, including the chemistry of the 
photosensitizer used, light intensity and wavelength, and oxygen concentration. As 
such, much attention is being focused on improving photosensitizers and light sources. 
A complex mixture of several partially unidentified porphyrins, named first 
generation photosensitizers, suffered from several limitations such as poor selectivity, 
need for large amounts of drug to obtain good efficiency, and high cutaneous 






compounds, named second generation photosensitizers such as porphyrin derivatives, 
phthalocyanines, napthalocyanine and chlorines were thus developed. These are 
effective generators of singlet oxygen, and have a strong absorption peak in the 
wavelength range of 650 - 800 nm, where light penetration in tissue is enhanced. 
Furthermore, their high selectivity for diseased tissues results in a better target-to-
healthy-tissue ratio and their relatively fast elimination from the body shortens side 
effects. An example of a second generation photosensitizer much utilized in PDT is 
zinc (II) phthalocyanine (ZnPc); it has high selectivity for tumour targets, enhanced 
cytotoxic efficiency due to singlet oxygen photogeneration, and because of its 
lipophilicity, the encapsulation of ZnPc in many drug delivery systems such as 
liposomes and polymeric micelles is facilitated. 
 
Selective photosensitizer delivery: Drug delivery is one of the main challenges in 
PDT to be overcome. As most photosensitizers are characterized by high lipophilicity, 
preparation of pharmaceutical formulations for parental administration has been 
highly hampered. Various encapsulation strategies have been studied to protect the 
hydrophobic photosensitizer from the aqueous environment. Delivery systems based 
on oil-dispersions, liposomes, polymeric particles (nanoparticles and microparticles) 
or hydrophilic polymer-photosensitizer conjugates have been developed, with varying 
degrees of success. Ideally, the drug delivery system should be biodegradable, have 
minimum immunogenicity, incorporate the photosensitizer without loss or alteration 
of its activity and provide an environment where the photosensitizer can be 
administered in monomeric form (reducing aggregation which can decrease singlet 
oxygen quantum yields). Most importantly, the drug delivery system should enable 






deliver therapeutic concentrations of the PDT drug to the target site with little or no 
uptake by non-target cells. A high selectivity of tumour targeting is extremely 
desirable to minimize the level of phototoxicity to healthy tissues as a drawback that 
has been associated with PDT is cutaneous photosensitivity, a side effect in patients 
which can be caused by the accumulation and prolonged retention of the 
photosensitizer in the skin. As such, the level of the administered photosensitizer in 
the skin should be as low as possible; high ratios of drug concentration in the tumour 
to that in the normal surroundings should also be achieved to minimize photodamage 
in the peritumoral tissue, especially in the case of infiltrating tumours where the 
irradiated area must also include the nearby normal tissue in order to obtain complete 
tumour eradication. 
 
Recently, drugs incorporated inside pH-sensitive polymeric micelles have shown 
improved tumour phototoxicity compared to Cremphor-EL formulations in vitro, but 
in vivo studies resulted in poor tumour regression and increased accumulation in 
normal tissues. All these techniques also suffer from the side effect – the free 
circulation in the body and accumulation in the skin and eyes of the PDT drug after 
controlled release and photosensitization, which results in phototoxic side effects, 
rendering the patient highly sensitive to light. 
 
1.3.2 Nanoparticles in PDT 
 
In a comprehensive review on delivery of PS for PDT, published in 2001, Konan et al 
divided the processes into passive and active based on presence or absence of a 






strategies used to deliver the PS specifically to diseased tissues using the target tissue 
receptors or antigens were termed ‘active’ while other formulations that enable 
parenteral administration and passive targeting namely, liposomes, oil-dispersions, 
polymeric particles and hydrophilic polymer–PS conjugates, were termed ‘passive’. 
This definition does not bring into consideration the role played by the nanoparticle 
carrier in the process of photocytotoxicity. This is understandable, as at that period, 
the only reported uses of nanoparticles were as controlled release vehicles for the PS. 
Subsequently, however, several formulations have been described whereby the carrier 
nanoparticles have an additional active intermediary role in the process of 
photodynamic activation. Therefore, for nanoparticulate carriers only, we have 
replaced the former structural classification with a functional one. Functionally, use of 
nanoparticles used in PDT can be broadly divided into two classes: as passive carriers 
and as active participants in PS excitation. Passive carriers can be sub-classified by 
material composition into (a) biodegradable polymer-based nanoparticles and (b) non-
polymer-based nanoparticles, e.g. ceramic and metallic nanoparticles. Active 
nanoparticles can be sub-classified by mechanism of activation (Table 1-2).  
 
Activation with NIR light for the possible use of light in the tissue transparent 
window has been explored via the novel concept of encapsulating photosensitizers in 
upconverting nanoparticles. In this strategy, the nanoparticles play the role of 
‘nanotransducers’, where the co-encapsulated upconverting donor ‘harnesses’ energy 
from the NIR light irradiated, activating the photosensitizing PDT drug, the acceptor. 







Table 1-2 Classification of nanoparticles used for photodynamic therapy  
 
 
Category Material Mechanism 
Passive / Carrier nanoparticles 
  Biodegradable Mainly PLA and 
PLGA  
Solid matrix/capsules containing PS; 
controlled release through biodegradation 
  Non-biodegradable Ceramic (Silica) PS is adsorbed/covalently bonded to 
porous shell; also used for co-
encapsulation with 2-photon dye 
Gold Nanoparticles (~5nm) act as pure 
carriers, no release 
Iron oxide Carries drug directly or co-encapsulated 
in micelle 
Polyacrylamide Encapsulates two-photon dye by 
microemulsion 
Active nanoparticles 
  Photosensitizer  CdSe Nanoparticles transfer energy from 
incident light directly to surrounding 
oxygen  
  Self-illuminating BaFBr:Eu+, Mn+ Scintillation (with afterglow) on 
excitation by X-rays activates attached 
PS 
  Upconverting 
   
NaYF4:Yb,Er/Tm Transduces low-energy light to higher 







1.4 Upconversion nanoparticles 
 
Luminescent materials absorb energy and subsequently emit the absorbed energy as 
light. These may be classified by excitation states into singlet or triplet. Emission 
from the excited singlet state is called fluorescence and the emitting materials are 
called fluorophores while emission from the triplet state is known as phosphorescence 
and the emitters named phosphors. Radiant emission can be categorized into two 
varieties based on the relative frequencies of the exciting and emitted radiations. In an 
overwhelming majority of cases, the emitted radiation is of a lower energy – and 
hence longer wavelength – than the exciting light. In other words, most fluorescent 
materials obey Stokes law. However, in a small number of instances, the emitted 
radiation actually possesses a higher energy and smaller wavelength than the exciting 
wavelength: the so-called Anti-Stokes emission or phosphorescence. Anti-Stokes 
emissions can take place in a number of ways, principal among them being 
upconversion, two-photon excitation and second harmonic generation. 
 
1.4.1 Principle of upconversion 
 
The exact mechanisms involved in upconversion are varied and complex and can be 
found to operate in isolation or in combination.(Auzel, 2004) In general, upconversion 
relies on sequential discrete absorption and luminescence steps which results in 
generation of shorter wavelengths. To generate upconversion luminescence, at least 
two metastable excited states are involved, the first serving as an excitation reservoir, 






suitable wavelength, both reservoir and emitter ions achieve a higher excitation state. 
However, instead of radiative dissipation of the energy, the reservoir ions non-
radiatively transmit the excess energy to emitter ions by lattice vibrations, thereby 
pushing it to a still higher excited state. The emitter ions then falls back to the ground 
state by emission of the excess energy as short wavelength radiation.  
 
Upconversion can be contrasted to simultaneous two-photon absorption (STPA), 
which requires a single excited state. The transition from ground to an excited 
electronic state is brought about by simultaneous absorption of two low energy 
photons whose combined energy is sufficient to induce the transition (Figure 1-5). 
Quantum mechanically, this takes place through the attainment of a virtual 
intermediate state on absorption of the first photon.  
 
Second-harmonic generation of higher wavelength radiations can occur through the 
weak wavelength dependent hyperpolarizability of a substance upon excitation with 
coherent radiation. This was first demonstrated by Franken in 1961, when they 
showed that ruby laser light propagating through a quartz crystal will generate light at 
second harmonic frequency with half the wavelength (Franken et al., 1961).  
 
Generally, STPA and second-harmonics are not efficient in generation of higher 
energy radiations. Upconversion, in contrast, is a much more efficient process, does 
not require coherent radiation, involves real intermediate states, and produces highly 
excited species that emit at significantly shorter wavelengths. Anti-Stokes emissions 









Figure 1-4 Upconversion involves energy transfer between two excited ion species, 
resulting in the acceptor ions reaching a higher energy state and subsequently emitting 











1.4.2 Upconversion nanoparticles: definition and materials 
 
Upconverting nanoparticles (UCN) are defined as modified nanometer-sized 
composites which generate higher energy light from lower energy radiation, usually 
near-infrared (NIR) or infrared (IR), through the use of transition metal, lanthanide, or 
actinide ions doped into a solid-state host (Boyer et al., 2006). These are sometimes 
referred to as ‘upconverting phosphors’ (UCP) and defined as ‘lanthanide-containing, 
submicrometer-sized, ceramic particles that can absorb infrared light and emit visible 
light’(Pires et al., 2006). Originally, the UCP were typically a few hundred 
nanometers in diameter and not nanoparticles in the stricter definition of the term 
which requires dimensions to be about 100nm or less. Upconverting phosphors have 
been commercialized under the term Up-converting Phosphor Technology™ by STC 
Technologies Inc. (merged with Epitope Inc in 2000 and now named Orasure Inc) 
who licensed the patents more than a decade ago. Commercial phosphors of about 
400nm diameter obtained from Orasure, Inc. have been used for recently reported 
experiments with microfluidic cassettes meant for DNA amplification through PCR 
(Wang et al., 2006). 
 
However, modifications in synthetic procedures have consistently reduced the particle 
size. Most synthetic procedures reported now describe phosphors in the region of 
100nm in dimension. Moreover, for most biological applications, the nanocrystal core 
is modified with suitable organic/polar shell molecules as well as other ligands for 
additional functionalities to generate a host of different nano-composites. These can 







Several ionic dopants possess the property of occupying metastable excited states 
that can exchange energy photons. Rare earth ions - both lanthanides and actinides - 
are particularly well known (Table 1-3). Since the first observations of upconversion 
in the mid-1960s, studies on upconversion involving most of the lanthanide and 
actinide ions have been reported, including observations of efficient three- or four-
quantum upconversion processes.  
 
For biological applications, the desired nanocrystalline core must have morphological 
and optical features that are suitable for conjugation with biological molecules as well 
as exhibit high intensity emission, leading to a detectable signal (Pires et al., 2006). 
Also, to get high quality nanocrystals, the surface properties need to be engineered 
and in some cases the growth dynamics of the nanocrystals need to be modulated. 
(Wang et al., 2006)  A variety of core materials and dopants have been demonstrated 
for upconversion particles with actual/possible biological applications (Table 1-3). 
Niedbala et al demonstrated the use of green-emitting Y2O2S phosphors doped with 
Yb and Er.(van De Rijke et al., 2001; Zijlmans et al., 1999) However, the particle size 
was of the order of about 400 nanometers. Lim et al demonstrated upconversion with 
nanometer dimensioned Y2O3 particles doped with varying amounts of Yb and 
Er.(Lim et al., 2006)  By varying the relative concentration of the dopants they 
obtained red and green emitting nanoparticles. Gudel et al. have recently identified 
micrometer-sized Er3+/Yb3+ or Tm3/Yb3+ co-doped hexagonal NaYF44 as the 
materials with the highest upconversion efficiencies (Heer et al., 2004) NaYF44 is 
being increasingly used as the core material of choice for upconverting particles with 






Table 1-3 Up-converting Phosphor Compositions 
 
Host Material Absorber ion Emitter ion Emission(s) 
Oxysulphides 
Y2O2S Ytterbium Erbium Green 
Y2O2S Ytterbium Thulium Blue 
Gd2O2S Ytterbium Erbium Red 
La2O2S Ytterbium Holmium Green 
Oxyhalides 
YOF Ytterbium Thulium Blue 
Y3OCl7 Ytterbium Terbium Green 
Fluorides 
YF3 Ytterbium Erbium Red 
GdF3 Ytterbium Erbium Green 
LaF3 Ytterbium  Green 
NaYF43 Ytterbium Thulium Blue 
BaYF5 Ytterbium Thulium Blue 
BaY2F8 Ytterbium Terbium Green 
Gallates  
YGaO3 Ytterbium Erbium Red 
Y3Ga5O12 Ytterbium Erbium Green 
Silicates 
YSi2O5 Ytterbium Holmium Green 






A simpler method is to grind the micrometer sized phosphors to obtain sub-micron 
sized particles (Soukka et al., 2005). Briefly, micrometer-sized UPC-phosphor 
particles are first ground in a small bead-mill, and thereafter phosphor particles with 
certain size and density are purified from the grinding suspension. However, this 
results in a wide size distribution which is unsuitable for quantitative assays. For 
example, one bio-assay report using ground particles reports diameters ranging from 
200nm to 400nm (average 280nm). (Kuningas et al., 2005)  
 
1.4.3 Surface modifications of upconverting nanoparticles 
 
The surface modification of the nanocrystalline core is important. As previously 
mentioned, surface properties determine the quality of the crystal. Perhaps more 
importantly, they also determine the solubility in physiologic solutions, stability over 
time and at altered pH conditions, and the ability to provide anchors for adding 
functional ligands like antibodies and drugs.  
 
There have been several reports of synthesis of up-converting nanoparticles (Heer et 
al., 2004; Heer et al., 2003; Yi et al., 2004; Yi et al., 2002; Zeng et al., 2005). 
However, most of these nanoparticles are synthesized in organic solvents (Heer et al., 
2004; Heer et al., 2003; Zeng et al., 2005) or at high temperatures (Yi et al., 2004; Yi 
et al., 2002) not compatible with most biologic materials. Surfactants such as cetyl-
trimethylammonium bromide (CTAB) or ethylenediamine tetraacetic acid (EDTA) are 
often used as ligands to control the particle growth and to stabilize the particles 
against aggregation. However, the synthesized nanoparticles are not soluble in 






attachment of biomolecules. Therefore, further surface modifications of the 
nanoparticles are required before they can be used for biological applications (Wang 
et al., 2005; Yi et al., 2004).  
 
Silica coating. Silica is less susceptible to pH dependent degradation in physiologic 
solutions than ligands bound by ionic interactions only. The stability of the coating 
also reduces the risk of toxicity from leaching of lanthanide ions into the body. Also, a 
greater range of emission frequencies can be achieved. Moreover, the surface 
chemistry of silica spheres is well documented and silica is known to have benign 
effects in biological systems. Initial reports dealt with the silica coated 
downconverting lanthanide doped phosphors. Beaurepaire et al engineered a silica 
shell over YVO4:Eu nanoparticles and functionalized the UCN with guanidinium for 
sodium channel targeting. Silica coated Gd2O3: Tb particles were functionalized with 
streptavidin by Louis et al. (Bazzi et al., 2004) Upconversion in silica coated 
lanthanide doped phosphor particles for bio-usage was first demonstrated by Niedbala 
and co-workers.(Niedbala et al., 2001; Zijlmans et al., 1999) In one example, the 
upconversion doped core was encapsulated with a uniform layer of silica (5-50nm 
thick) by hydrolysis of tetraethylorthosilicate and functionalized with amino groups 
by 3-aminopropyltriethoxysilane.(van De Rijke et al., 2001) The surface amino 
groups provide the necessary anchor for attachment of other biomolecules. In this 
report, the aminated surface was functionalized with biotin-poly(ethylene glycol) 
using N-hydroxysuccinimidyl (NHS) ester coupling.(van De Rijke et al., 2001) Silica 
coating has proved popular for the use of the phosphors in nucleotide assays because 
the amine modified DNA strands can be attached directly to the  SiO2 (Zhang et al., 






synthesized phosphor particles with NeutrAvidin by physically adsorbing the latter on 
the surface of the particles without any other modifications or coatings.(Zijlmans et al., 
1999) However, this approach runs the risk of desorption of the adsorbed molecule 
when used for some period of time in biological solutions. Desorption rate will also 
depend on the pH of the medium.  
 
Surface modification with silica is very dependent on the surface chemistry of the 
nanoparticles. For example, it is difficult to directly make silica coatings on 
hydrophobic nanoparticles unless they are previously made hydrophilic or some 
specially designed silane precursors (e.g. tetraethylorthosilicate in the above example 
(van De Rijke et al., 2001)) are used. Also, the layer of silica increases the size of the 
particles by 5 to 50 nm depending on thickness of the film. An alternative route is to 
use bio-polymers for the surface coating. However, the harsh reaction conditions that 
are part of the synthetic process limit this possibility. 
 
Polymeric coatings. Chitosan, a natural biopolymer, has been shown to be 
hydrophilic, biocompatible and biofunctional. It has been widely used as scaffolding 
material for tissue engineering and as a carrier for drug and gene delivery. 
Furthermore, chitosan has amino and hydroxyl groups, which can be used to further 
attach biomolecules. Wang et al developed a very straightforward method to prepare 
water soluble chitosan/LaF3:Eu3+ nanocrystals with functional chemical groups on 
their surfaces.  
 
Polyvinylpyrrolidone (PVP) is an amphiphilic surfactant which can render the 






groups can coordinate with lanthanide ions. Li and Zhang demonstrated PVP as both 
the chelating agent and stabilizer to synthesize NaYF4 nanocrystals with controlled 
size and shape, and with suitable surface property and solubility in water. The PVP-
stabilized NaYF4 nanocrystals could be directly coated with a uniform layer of silica 
to produce a surface for the conjugation of biomolecules. 
 
Conjugation of biomolecules on the surface of phosphor particles by a carboxyl-group 
growing process was reported by Kubitschko et al (Kubitschko et al., 1997) and used 
for attachment of streptavidin in bioassays (Kuningas et al., 2005). In short, after 
careful bath sonication the phosphors were suspended in aqueous solution of Additol 
XW330, an ammonium salt of poly(acrylic acid) and slowly agitated overnight at 
room temperature to develop carboxylic acid groups onto the surface of phosphor 
particles. After adequate washing, the particles are transferred to suitable buffer 
solutions and the desired ligand (e.g. streptavidin) could then be conjugated to the 






1.5 Thesis overview 
 
While nanoparticles have enormous potential in different aspects of biomedicine, 
much needs to be done and many avenues explored before that promise can be 
realized. The major impetus for novel applications with this new technology is 
coming mainly from material scientists, and in fact, nanotechnology is still very much 
the domain of the material scientist. As new materials are synthesized in the 
nanometer scale, new properties and applications are being discovered and 
implemented in biological systems. In this thesis, novel organic polymer coated 
upconverting phosphor nanoparticles have been synthesized and characterized for 
solving biomedical problems (Chapter 2). 
 
Luminescent biological labels are invaluable as probes for molecular labeling (Fu et 
al., 2005). Current materials such as organic dyes and quantum dots have some 
limitations. Organic dyes have poor photostability, broad absorption and emission 
spectra. Semiconductor based quantum dots arel controversial because of the risks 
posed by the inherent toxicity of its components. Moreover, conventional fluorescent 
labeling materials such as organic fluorophores (e.g. fluorescein) and quantum dots 
are usually excited by ultraviolet (UV) light and emit fluorescence in the visible range. 
UV light has several disadvantages: long-term irradiation of living cells causes DNA 
damage and cell death, significant auto-fluorescence from biological tissues reduces 
signal-to-background ratio, and for purposes of in vivo imaging the short penetration 








Upconversion nanoparticles, on the other hand, absorb near infrared light (NIR) and 
emit in the visible range. NIR radiation excited optical imaging of living cells and 
tissues is expected to have a major impact in biomedical research involving short 
radiation path-lengths, as in small animals and superficial human tissues. NIR 
radiation is less harmful to cells and minimizes auto-fluorescence from biological 
tissues .(Frangioni, 2003) In the first part of this doctoral thesis, I have explored the 
use of upconverting nanoparticles in imaging applications as live cell and tissue 
imaging label (Chapter 3 & 4).  
 
Photodynamic therapy has emerged as one of the important therapeutic options in 
management of cancer and other diseases. PDT utilizes light-sensitive drugs or 
photosensitizers (PS) that can be preferentially localized in malignant tissues. Its 
therapeutic effect is activated by photoexcitation of the localized photosensitizer to 
generate a cytotoxic species, e.g., singlet oxygen (1O2), free radicals, or peroxides. 
This leads to selective and irreversible destruction of diseased tissues, without 
damaging adjacent healthy ones. Despite its advantages over current treatments, PDT 
is yet to gain general clinical acceptance. There are several technical difficulties in the 
application of PDT to a wide range of diseases. First, currently FDA approved PDT 
photosensitizers absorb in the visible spectral regions below 700 nm, where light 
penetration into the skin is only a few millimeters, thus clinically limiting PDT to 
treating topical lesions. Second is the difficulty in preparing pharmaceutical 
formulations that enable parenteral administration because most existing 
photosensitizers are hydrophobic and aggregate easily under physiological condition. 
Thirdly, the accumulation selectivity to diseased tissues is often not high enough for 






Nanoparticles offer solutions to each of the three difficulties. Nanoparticles carrying 
PS by different strategies (adsorption/covalent bonding) offer benefits of 
hydrophilicity and appropriate size for passive targeting to tumor tissues by the 
enhanced permeability and retention (EPR) effect. Selective accumulation can be 
enhanced by using surface modification to bind monoclonal antibodies or specific 
tumour-seeking molecules to PS loaded nanoparticles. Use of nanoparticle-
encapsulated two-photon dyes or upconversion nanoparticles allows activation with 
low energy light which can deeply penetrate tissues. In this report we discuss the 
development of a ‘nano-transducer’ based on this principle (Chapter 5). 
  
A short description of the subsections of this thesis has been provided for the purposes 
of a rapid overview: 
 
Step 1: Fabrication and characterization of multi-functional upconversion 
nanoparticles (Chapter 2) 
The first section deals with the synthesis and characterization of the upconversion 
nanoparticles.  The physical dimensions, the nature of the chemical covering and 
optical properties of the particles have been determined. The effect of the particles on 
cells in vitro has also been studied to determine biocompatibility. 
 
Step 2: Upconversion nanoparticles for targeting cancer cells in vitro (Chapter 3) 
The second section involves the application of these UCN as targeted fluorescent 
probes against cell surface molecules of cancer cells. The particles have been 
modified with a cancer cell targeting ligand and sensitivity and specificity of this 






Step 3: Upconversion nanoparticles for imaging in animal tissues (Chapter 4) 
The special in vivo imaging capability of these nanoparticles is explored. The 
nanoparticles are imaged after injection at different depths in different tissues in rats. 
The nanoparticles are also tagged to cancer cells and these cells are imaged after 
injection into mouse tissue.  
 
Step 4: Fluorescent nanoparticles for photodynamic therapy of cancer cells 
(Chapter 5) 
In this section we propose the concept of UCN for photodynamic therapy of cancer. 
This therapeutic capability is demonstrated in cancer cells in vitro. The different 
parameters are explored and the possibility of extension of this therapy to clinical 






















As noted earlier (Section 1.4.2) upconverting nanoparticles (UCN) are modified 
nanometer-sized composites composed of a solid-state host containing doped 
transition metal, lanthanide, or actinide ions. Of the several ionic dopants that possess 
the property of occupying metastable excited states capable of exchanging energy 
photons,  rare earth ions - both lanthanides and actinides - are most popular (Table 1 
3).  
 
Use in biological samples imposes some conditions on UCN structure and 
composition. The surface of the nanoparticles should be charged (for solubility in 
physiologic solutions) and non-toxic. This is usually achieved with a coating (usually 
with a bio-polymer or silica) and therefore the nanocrystalline core must be suitably 
chosen. As noted earlier, Er3+/Yb3+ or Tm3/Yb3+ co-doped hexagonal NaYF4 are the 
materials with the highest upconversion efficiencies (Heer et al., 2004). The inter-
ionic distance for the dopants in the crystalline nanoparticles matrix have not been 
reported. 
 
The schematic of the proposed nanoparticle is shown (Figure 2-1). It is composed of a 
crystalline matrix (a ‘nanocrystal’) of NaYF4, co-doped with the lanthanide ions 
Ytterbium and Erbium. The surface of the nanocrystal is composed of a layer of high 
molecular weight polyethylene imine (PEI). Polyethylene imine (PEI) is a hydrophilic 
polymer with primary, secondary and tertiary amino groups (in the ratio of 1:2:1) and 
an overall positive charge. The positively charged amino groups stabilize the 






PEI is a highly branched polymer with an appreciable thermal stability, which makes 






Figure 2-1 Upconverting Nanoparticle: schematic representation 
 
The approximate decomposition temperatures are 290oC for the 0.8kD PEI and 310oC 
for the 25kD PEI, sufficiently above the required reaction temperature of 200oC. Free 
PEI has been reported to be toxic to cells, but when in particulate form, the 
detrimental effects are greatly lessened (Godbey et al., 1999). A possible reason for 
toxic effects of free PEI on cells is that it will permeabilize bacterial and certain 
synthetic membranes. The toxic effect is usually seen in bacterial cell membranes 
(Helander et al., 1997) and in mammalian hepatocytes when used in high 






demonstrate no toxic effects at normal concentrations (for e.g. in neuronal cells 
(Lambert et al., 1996)).  
PEI contains a large number of amino groups in the long molecular chain, which are 
capable of forming complexes with metal ions via coordination (Kobayashi et al., 
1987). High molecular weight PEI with more coordination sites per molecule 
compared to low molecular weight PEI can bind to the nanoparticle surface more 
tightly and thus is more efficient to control the particle growth and stabilize the 
particles against aggregation. The following studies are all based on the NaYF4 








2.2 Materials and Methods 
 
2.2.1 Reagents  
 
Ammonium fluoride (NH4F, 98+%), boric acid (99.99%), dimethyl sulfoxide (DMSO, 
≥99.5%), 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC), erbium oxide 
(Er2O3, 99.99+%), FA (approx. 98%), MEM non-essential amino acid solution, N-
hydroxy-succinimide (NHS), polyethylenimine (PEI, branched polymer 
(−NHCH2CH2−)x(−N(CH2CH2NH2)CH2CH2−)y, 25 kDa), sodium chloride (NaCl, 
≥99.0%), sodium azide (99.99+%), sodium pyruvate (≥99%), yttrium chloride 
hexahydrate (YCl3·6H2O, 99.99%) and ytterbium oxide (Yb2O3, 99.99%) were 
purchased from Sigma-Aldrich. Dulbecco’s modified Eagle’s medium (DMEM), fetal 
bovine serum (FBS), penicillin-streptomycin, Rosewell Park Memorial Institute 
(RPMI) 1640 and trypsin-EDTA (0.5% trypsin with EDTA-4Na) were purchased from 
GIBCO Invitrogen. Fluorescein (FITC)-streptavidin was purchased from Biomeda. 
Red emitting quantum dots were purchased from American Dye Sources, Inc. These 
are standard CdTe QDs with sodium salts of carboxylate groups on the surface. 
 
All of the reagents were used as received without further purification. PEI stock 
solution (5 wt%) was prepared by dissolving PEI in DI water. YCl3 and NaCl stock 
solutions (0.2 M) were prepared by dissolving YCl3·6H2O and NaCl respectively in 
DI water. YbCl3 and ErCl3 stock solutions (0.2 M) were prepared by dissolving 







2.2.2 Synthesis of PEI/NaYF4 nanoparticles 
 
A new hydrothermal synthetic procedure for upconversion nanoparticles had been 
recently developed in our laboratory and published.(Wang et al., 2006) The 
nanoparticles were synthesized using this method. The primary advantage of this 
method is a simple, one pot reaction that precludes separate steps for surface 
modification of the nanoparticles.  
 
PEI/ NaYF4:Yb,Er nanoparticles were synthesized by this hydrothermal method. 10 
ml of NaCl, 8 ml of YCl3, 1.8 ml of YbCl3, and 0.2 ml of ErCl3 solutions were added 
to 60 ml of ethanol containing 20 ml of 25kDa PEI solution. The mixture was poured 
in a Teflon-lined autoclave flask and heated to 200 °C for 24 h with stirring. This 
resulted in the formation of the nanoparticles coated with PEI. 
 
After cooling, the nanoparticles were centrifuged down, washed alternatively with 
ethanol and DI water several times, and vacuum-dried at ambient temperature. The 
nanoparticles were stored in ethanol (99.7%). 
 
2.2.3 Physical characterization of the nanoparticles 
 
Size and shape determination by Transmission Electron Microscopy: 
Transmission electron microscopy (TEM) can be used for direct determination of 
shape and size of nanoparticles, although it is to be kept in mind that only a very small 
representative sample of the nanoparticles can be seen in each field. The TEM 






operating at an acceleration voltage of 200 kV. 
 
Sample preparation: A small drop of PEI/NaYF4:Yb,Er nanoparticle solution in 
ethanol was put on a 50 Å thick carbon-coated copper grid (300 mesh). The excess 
solution immediately removed by gently touching the sides with laboratory grade 
filter papers. The samples were imaged with the help from staff at the Electron 
Microscopy Unit at the National University of Singapore. 
 
Quantification of surface charge: The surface charge of a particle in solution is 
measured by measuring the zeta potential. The zeta potential of a nanoparticle in 
solution can be determined by its mobility in a charged field after discounting the 
effect of size. This is done by dynamic light scattering measurements to determine the 
speed of Brownian motion of the particles. The measurements were done using the 
Zetasizer NanoZS (Malvern Inst., Malvern, UK) using a PBS solution of the 
nanoparticles at a temperature of 24°C. 
 
Sample preparation: 0.9 ml PEI/ NaYF4:Yb3+,Er3+ nanoparticles (1 mg/ml) in PBS 
was filled in a special polystyrene sizing cuvette. This was placed in the Zetasizer 
NanoZS chamber and the zeta potential measured at the given parameters. 6 readings 
from 6 samples were recorded and the average used.  
 
Size distribution and presence of aggregates: The absolute size of the nanoparticles 
measured using dynamic light scattering in solution is not the true size but includes 
the hydrodynamic radius of the layers of water molecules attached to the surface of 






the distribution of sizes of nanoparticles, determined using dynamic light scattering, 
provides a valuable indicator of the presence of aggregates in solution. Presence of 
aggregates shows up as a bimodal peak in the size distribution.  
 
The distribution of sizes present in the nanoparticle solution was measured using 
Zetasizer NanoZS (Malvern Inst., Malvern, UK). The parameters and sample 
preparation was similar to the ones followed for determination of surface charge. 6 
different samples were used to generate 6 different distribution patterns. 
 
Determination of elemental composition: The synthesis reaction results in a 
complex nanoparticle which should have the two lanthanide dopants in the matrix in 
appreciable amounts. To determine the presence and relative amount of each of the 
element in the nanoparticles, elemental composition is needed to be determined. There 
are several methods to determine elemental composition. One of the most sensitive is 
mass spectrophotometry using inductively coupled plasma (ICP-MS).  
 
Sample preparation: Since ICP-MS loses sensitivity at high concentrations, a very 
dilute solution of the nanoparticles was prepared (44µg/ml) in de-ionized water. 10ml 
of this solution was sent for analysis by ICP-MS at the Elemental Analysis Laboratory, 
Department of Chemistry at the National University of Singapore.  
 
Determination of presence of PEI on the nanoparticle: While the elemental 
analysis tells us about the core composition, the presence of PEI on the surface 
remains to be determined. The presence of PEI is essential for solubility of the 






surface require detection by another very sensitive technique - namely the Fourier 
transform infrared spectroscopy (FTIR).  
 
Sample preparation: Since only dried powder samples are used for the FTIR, 
concentrated samples of the nanoparticles solution in alcohol were placed in an open 
glass petri dish and vacuum dried overnight. Two samples were used: one containing 
nanoparticles obtained in the described procedure, and the other where the PEI was 
not added in the synthetic procedure. The white residues left on the dishes were 
carefully scraped off and mixed thoroughly with 0.15gm of potassium bromide (KBr) 
powder with a mortar and pestle. The mixture was then compressed into pellets of 
fixed dimensions using a hand press and maintaining a pressure of 5000 psi for 10 
minutes. The pellet was loaded into the sample chamber on a Bio-Rad FTS156 
spectrometer and the transmission spectra recorded. 400 readings were obtained for 
each sample and averaged to cancel out random noise. 
 
2.2.4 Optical characterization 
 
Fluorescence emission spectra measurement: The synthesized nanoparticles 
contain lanthanide ions doped into a nanocrystalline matrix. This allows upconversion 
fluorescence upon stimulation with infra-red radiation.  The emission spectra can be 
seen with naked eyes by placing a cuvette containing nanoparticles in the path of an 
infrared laser. To determine the emission spectral frequencies, a fluorescence 








Sample preparation: 2ml of a relatively concentrated solution of nanoparticles 
suspended in de-ionized water was taken in a cuvette and placed in the sample holder 
of a SpectroPro 2150i spectrophotometer (Roper Scientific Acton Research, MA) 
equipped with a 1200 g mm-1 grating and a 980 nm VA-II diode pumped solid state 
(DPSS) laser (current set at 1.50 A). The emission was measured over a range of 
wavelengths from 400nm to 700nm at a step of 1nm. 
 
Photostability of emission: Almost every known fluorescent probe photobleaches, i.e. 
loses its fluorescence efficiency after exposure to excitation light. Some, like green 
fluorescent protein, loses its fluorescence rapidly and cannot be used for extended 
exposure or long term tracking of samples. Therefore it is important to determine how 
the fluorescence efficiency of the upconversion nanoparticles is affected by laser 
exposure.  
 
Sample preparation: 100 µl of PEI/ NaYF4:Yb3+,Er3+ nanoparticles (4.4 mg/ml) was 
vacuum-dried on microscopic glass slide (76 × 26 × 1 mm). The glass slide was 
positioned in the sample chamber of a SpectroPro 2150i spectrophotometer (Roper 
Scientific Acton Research, MA) equipped with a 1200 g mm-1 grating and a 980 nm 
VA-II DPSS laser (current set at 1.50 A) such that the infrared laser focuses on the 
dried sample. Using a dried sample prevents alteration in concentration due to solvent 
evaporation or nanoparticle settling. The dried sample was focused with continuous 
NIR excitation for nearly 7 hours. For quantification, the fluorescence peak in the 








Effect of storage on emission efficiency: Different media affect the emission 
efficiency of nanoparticles differently. For most purposes, nanoparticles required to be 
used in biological media are stored in PBS. Therefore it is necessary to understand the 
effect on emission efficiency of nanoparticles on prolonged storage.  
 
Sample preparation: 1 ml of nanoparticles in PBS was placed in a cuvette and gently 
shaken to ensure even dispersion. The emission spectrum was recorded with a 
SpectroPro 2150i spectrophotometer with a 980 nm VA-II diode pumped laser. The 
cuvette was removed and incubated at room temperature. The measurements were 
repeated over 12 days with slight shaking of the sample before each scan. The peak 
emission from the different spectra were compared. 
 
Effect of incubation on fluorescence: When nanoparticles are used for biomedical 
applications, they face a different situation from storage conditions. In vitro, 
nanoparticles are commonly exposed to media containing a mixture of DMEM (a 
mixture of salts and amino acids) and serum derived from calf or other bovine sources. 
In vivo, the nanoparticles are exposed to blood, which is about half serum and half 
cells. Hence, it is important to understand the effect of serum on the emission 
efficiency of nanoparticles. If the emission is found to degrade, this imposes a limit on 
the duration of usage of the nanoparticles. Also, the effect of the different parameters 
like temperature and concentration need to be determined to understand more fully the 
cause of emission degradation and the limits of usage of these nanoparticles in vitro 








Step 1- Effect of media: To determine the effects of different media, 1 ml of 
nanoparticle suspension each was added to 1 ml of FBS, 1 ml of DMEM and 1 ml of 
de-ionized water (as control). The mixtures were vortexed to mix the components 
thoroughly. The mixtures were then transferred to cuvettes and the emission spectra 
were obtained with the spectrophotometer. The cuvettes were then transferred to an 
incubation chamber maintained at 37°C. At intervals, the cuvettes were taken out, 
gently vortexed to guard against uneven settling of the particles, and emission spectra 
obtained from the spectrophotometer.  
 
Step 2 – Effect of temperature: To determine if the effect of serum on fluorescence 
efficiency is temperature dependent 3 ml of nanoparticle suspension was added to 3 
ml of FBS, vortexed to mix thoroughly and divided into 3 different cuvettes. The 
cuvettes were stored at 37°C, 4°C and -20°C. At intervals, the cuvettes were taken out, 
the frozen cuvette was warmed until liquefied, all the cuvettes gently vortexed to 
guard against uneven settling of the particles, and emission spectra obtained from the 
spectrophotometer.  
 
Step 3 – Recovery of fluorescence: To determine the effect of washing and 
trypsinization on incubated nanoparticles, the cuvettes containing nanoparticles 
incubated with DMEM, FBS and DI water were incubated at 37°C for 15 days as 
described in the previous section. The contents of the cuvettes were transferred 
centrifuge tubes. The nanoparticles were centrifuged down at 13000 rpm for 10 
minutes and washed thrice in DI water. Finally the particles were re-suspended in 2 
ml of DI water, transferred back to fresh cuvettes, and emission spectra obtained from 






pelleted down, and re-suspended in 500µl of trypsin and incubated at 37°C for 30 
minutes. The particles were washed thrice in DI water, re-suspended in 2ml of DI 
water and the emission spectra obtained from the spectrophotometer. 
 
2.2.5 Cell biocompatibility test 
 
Cell culture: A number of different cells lines were cultured and maintained and used 
in different experiments. These included HT29 cells (human colon adenocarcinoma 
cells), MCF7 cells (human breast adenocarcinoma cells), NIH-3T3 cells (human 
immortalized fibroblast cells), OVCAR3 cells (human ovarian cancer cells).  The 
cells were cultured in a media constituted of DMEM, FBS and antibiotics 
(streptomycin and penicillin) in a ratio of 100:10:1 in 75 cm2 flasks. The cells were 
incubated in a 100% humidified incubator with 5% CO2 at 37 
oC.  
 
The culture flasks were observed under 10× objective using Leica DM IRB 
microscope (Leica, Germany) every 4-7 days to examine the cell confluency and to 
detect the presence of any contamination. Subculture was performed every 4-7 days. 
Media was first removed from the culture flasks and the flasks were washed with 10 
ml of PBS. 2.5 ml of trypsin was added to each flask to detach the cells and the flasks 
were placed back in the incubator for 5 minutes. 2.5 ml of culture media was then 
added to the flasks to stop the action of trypsin. The cells were centrifuged down at 
1,200 rpm and resuspended in culture media to be reseeded into new culture flasks.  
 
To count the cells, the hemocytometer and glass coverslip were cleaned with 70% 






that the total volume for each of the nine 1 mm2 squares is 0.1 mm3. Two drops of cell 
suspension was pipetted into the edge of one of the V-shaped wells of the 
hemocytometer and the suspension was spread evenly by capillary action. The 
hemocytometer was observed under 10× objective using Leica DM IRB microscope 
(Leica, Germany) and the cells in the four corner squares were counted. Only the cells 
on the top and the left-hand lines of each square were included to prevent double 
counting of the cells. The average number of cells in each square was used to 
calculate the cell concentration: 
 
Cell concentration (cells/ ml) = Average number of cells per square × 104 
 
Protocol for biocompatibility test: PEI has been widely used for bioapplications, 
especially for gene delivery, for many years (Babacan et al., 2000; Bahulekar et al., 
1991; Baker et al., 1997; Kircheis et al., 2001; Lvov et al., 1995). To evaluate the 
biocompatibility of the nanoparticles, human colon HT-29 cells were grown with the 
medium containing PEI/NaYF4:Yb,Er nanoparticles and the cell viability was 
determined using a MTT assay.  
 
MTT assay: To assess the biocompatibility of the nanoparticles, HT29 cell lines were 
grown with the nanoparticles and the cell viability was measured by MTT assay. Cells 
were cultured in a 96-well plate (approximately 50 000 cells per well) with 300 µl 
medium containing different concentrations of the nanoparticles for 6 h. Then, 20 µl 
of MTT solution (5 mg ml-1 MTT in phosphate buffer solution, pH 7.4) was added to 
each well and incubated for further 2 h at 37 ◦C. After removing the medium, the 






µl of DMSO and quantified by measuring the absorbance of the cell lysate at 595 nm. 
To test long term effect of the nanoparticles on HT-29 cells, cells were plated in a 96-
well plate (10 000 cells per well) and incubated with nanoparticles for 2 weeks. The 
media of the wells were changed every 48 hours to ensure proper environment for cell 
survival. At the end of 2 weeks, cell viability was assessed using MTT assay as 
described above. Cell viability was expressed as a percentage of the control. All 






2.3 Results and Discussion 
 
2.3.1 Physical characterization of the nanoparticles 
 
Physical characterization provides a basic understanding of physical structure of the 
nanoparticle. It consists of determination of size, shape, charge, composition of core 
elements and presence of surface polymer. It also involves detection of aggregate 
formation in solution.  
 
2.3.1.1 Nanoparticle size measurement using TEM 
 
A ‘one-pot’ hydrothermal synthetic procedure was used to synthesize the PEI/NaYF4 
nanoparticles. The resultant solution of nanoparticles in DI water was clear and free of 
visible aggregates. The nanoparticles were isolated by centrifugation and vacuum 
drying and re-suspended in alcohol and deionized water. 
 
Transmission electron microscopy (Figure 2-2) demonstrated that these are well 
separated spherical particles having a mean particle size of about 50 nm with a 
relatively narrow size distribution. The sub-100 nm size is very important because it 
means these particles can be used in vivo. Particles above this diameter are more 
prone to be trapped by the endothelial barrier and cannot reach target sites. The visible 
separation of the particles is also very important because it is an indicator that there is 
not much aggregation in solution and these particles can be used for biomedical 







Some of the nanoparticles are found in clusters in the TEM picture (Fig 2.2 A). A 
higher magnification view of the clusters (Fig 2.2 B) shows that the nanoparticles are 
loosely placed close to each other rather than sticking to form the solid mass that is a 
feature of aggregation. The loose clustering is an artifact of the process of sample 
preparation whereby the drop of nanoparticle solution dried on the copper grid forces 




Figure 2-2 (A) TEM image of NaYF4:Yb,Er nanoparticles with high molecular 
weight PEI. (B) The same particles at higher magnification.  
 
2.3.1.2 Elemental analysis of the nanoparticles 
 
To determine if the synthetic process resulted in appropriate doping of the 
nanocrystalline core, the relative abundance of the core materials need to be 
determined. Elemental analysis of the nanoparticle suspension was done using 






per million) were obtained. 
 
Y  =  20.24 
Na  =    2.31 
F  =    2.44 
Yb  =    4.82 
Er  =    1.45 
 
The ratio of energy donor ions (Yb) to emitter ions (Er) is about 3.3. Presumably, the 
relative higher concentration of donor ions ensures that there is a high efficiency of 
energy transfer to emitter ions. It may be noted that during synthesis, the 
corresponding ratio was 8.7.  Thus, there is a differential doping of the elements to the 
nanocrystalline matrix.  
 
Expectedly, the elemental composition demonstrated the preponderance of Y in the 
nanoparticles’ core matrix. The large preponderance of Y in the final nanoparticle 
composition is especially important for highly sensitive detection of the particles in 
tissues. Since Y is normally absent in tissues or present in quantities too minute to be 
detected, using ICP for detection of Y in a digested tissue sample is a very sensitive 
method to test for the presence of the nanoparticles.  
 
2.3.1.3 Zeta potential measurement 
 
The zeta potential is an indication of the mean surface charge of the nanoparticles. 






solutions. Higher surface charge prevents aggregation in solution by creating a large 
shell of water molecules around the nanoparticle. It may be recalled that these 
nanoparticles are coated with PEI, which is a polymer with positively charged amino 
side groups. Thus, we expect that the zeta potential, measured by dynamic light 
scattering of the particles in a charged field using the Zetasizer, would be positive. 
 
Zeta potential of PEI/NaYF4:Yb,Er nanoparticles measured using Zetasizer was:  
 
ζ  =  + 0.00435  (n = 6) 
 
A larger value of zeta potential is to be expected. The smaller value seems to argue 
against the presence of PEI on the nanoparticles. To confirm the presence of PEI, FT-
IR studies of the UCN were subsequently carried out. 
Variation in individual readings was most likely due to the non-uniform distribution of 
chemical groups attached on the surface of the nanoparticles. Because salt solutions 
tend to reduce the layer of water molecules arranged around the nanoparticles, these 
nanoparticles lose some of their solubility in solutions with higher salt concentrations.  
 
2.3.1.4 Size distribution and detection of aggregates 
 
While the TEM images provide an indication of the uniformity of sizes of the 
nanoparticles and the absence of aggregation, it is based on a very small sample size 
and can be erroneous. Therefore it is necessary to quantify these parameters to ensure 







This is done using dynamic light scattering (DLS), using the Zetasizer, to measure the 
rate of Brownian diffusion in solution. From the values obtained, a graph of relative 
percentages of particles of different sizes present in solution can be obtained. This 
graph is then analyzed to measure the degree of uniformity of particle sizes by 
calculating the polydispersity index (PDI).  
 
In physiological buffer: 
 
PDI = 0.372 (n = 6 samples, S.D. = 0.083) 
 
PDI values of less than 0.2 indicate highly uniform particles, while PDI values 
between 0.2 and 0.5 indicate moderate uniformity only. From the obtained value it 
appears that the nanoparticles are only of moderately uniform size with some 
variation existing between the particles. 
 
Apart from PDI, DLS can also be used to determine presence of aggregates. 
Aggregates of nanoparticles are several times the size of individual nanoparticles and 
show up as a separate peak in the graph of particle sizes. For this sample, DLS 
demonstrated unimodal size distribution of the nanoparticles implicating 
monodispersity in solution.  Hence it confirms the visual impression of the TEM 
pictures that the particles are well separated and relatively uniform in size. 
 
While DLS has been used to determine size of uniform nanoparticles, this is often not 
accurate, especially for nanoparticles with charged surface in water. This is because 






molecules surrounding the nanoparticle surface, i.e. it is the hydrodynamic radius and 
not the true radius. In the case for these UCN also, the measured diameter in PBS 
using DLS was several times larger than that determined by TEM. 
 
2.3.1.5 Detection of PEI on nanoparticle surface 
 
It is important to conclusively demonstrate the presence of PEI on the surface of the 
nanoparticles. Fourier Transform Infrared spectrophotometry (FTIR) was used to 
obtain spectra (averaged over 400 readings) from two samples of nanoparticles – one 
obtained in the method described above, and another sample made without the PEI 
added in the synthetic procedure. The FTIR spectra of the PEI/NaYF4:Yb,Er 
nanoparticles (Figure 2-3 b) was compared with that from pure NaYF4:Yb,Er 
nanoparticles synthesized without PEI (Figure 2.3 a). Presence of the unique 
absorption peaks from internal vibration of amide bonds (1380-1630 cm-1) and CH2 
stretching vibrations (2850-2960 cm-1) are noted in the spectrum from 
PEI/NaYF4:Yb,Er nanoparticles only, but not in the spectra obtained from the control 


































Figure 2-3 FTIR spectra of pure PEI/NaYF4:Yb,Er nanoparticles (a) and 
NaYF4:Yb,Er nanoparticles (b). 
 
The physical characterization of the nanoparticles determined that the particles are 
roughly spherical in shape and about 50nm in diameter with a relatively small 
diversity in size among particles; they carry a surface charge which is positive, and 
this prevents aggregate formation in solution; they are composed of Yb and Er doped 
(in a ratio of about 3.3:1) in a matrix containing an excess of Yttrium, and coated with 
PEI which presumably gives these particles their positive charges.  
 
2.3.2 Optical characterization of the nanoparticles 
 
The optical characterization explores the factors and parameters that affect the 







2.3.2.1 Fluorescence spectra measurement   
 
When a solution of nanoparticles in a cuvette was excited with 980nm near infra-red 
(NIR) laser in a fluorescence spectrophotometer, the particles emitted fluorescence 
with dual peaks are at 653nm and 540nm, which are in the red and green regions of 
the visible spectrum respectively (Figure 2-4A).  The combination of these two peaks 
result in a resultant fluorescence which appears greenish-yellow as can be seen when 
the cuvette is excited with the laser outside the spectrophotometer (Figure 2-4B).  
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Figure 2-4 A. Emission spectra of the nanoparticles on excitation at 980nm. The peaks 
are in the red (655nm) and green (550nm) regions of the visible spectrum. B. 
Photograph of the PEI/NaYF4:Yb3+,Er3+ nanoparticles in  aqueous solution. 
 
The green peak has a larger area under the curve than the red peak. This means that all 
other things being equal, when excited, the brightness of the green emission will be 
more than that of red. Thus the green emission has been used for most in vitro 
emission studies. However, since red light penetrates deeper than green in mammalian 






very narrow full width at half maximum (FWHM) values of about 16 and 24 nm for 
the green and red regions respectively. The relative sharpness of the peaks can be 
compared with those from other fluorescent nanoparticles: FWHM values for most 
quantum dots are typically around 30 to 50 nm (Michalet et al., 2005). The NIR 
excited quantum dots recently reported in the literature for live cell and in vivo studies 
tend to have even larger FWHM in the region of 100nm (Table 2-1 Narrowness of 
emission peak as determined by full width at half maximum (FWHM): 
comparison between different NIR excited semiconductor nanoparticles..  
 
 
Table 2-1 Narrowness of emission peak as determined by full width at half maximum 
(FWHM): comparison between different NIR excited semiconductor nanoparticles. 
 
NIR excited nanoparticles FWHM (nm) References 
PEI/NaYF4:Yb,Er : Green peak 16 (Chatterjee et al., 2007) 
PEI/NaYF4:Yb,Er : Red peak 24 (Chatterjee et al., 2007) 
QD655-Luc8 (approx) 30 (So et al., 2006), 
Phosphine/CdTe(CdSe) 90 (Kim et al., 2004; Parungo 
et al., 2005; Soltesz et al., 
2006; Soltesz et al., 2005) 
BSA/CdMnTe (approx) 90 (Morgan et al., 2005) 
Phosphine/ZnSe/InP/InAs0.82P0.18 120 (Kim et al., 2005) 
BSA/CdMnTeHg (approx) 130 (Morgan et al., 2005) 
Where values are not stated explicitly in the literature, they have been approximated 
from presented spectral data (noted as approx).  
 






other fluorescent labels with different emission wavelengths without overlap. The 
dual signal character presents a unique advantage to these nanoparticles: NaYF4 
nanoparticles fluorescent images can be extracted into red or green channels without 
loss in signal strength, in contrast to single channel QDs. Therefore, it can possibly be 
used as a ‘universal’ probe for multiplexing with any other single channel fluorescent 
nanoparticle for simultaneous detection, and the relevant information abstracted from 
the image using different color channels.  
 
 
2.3.2.2 Quantum Yield 
 
The fluorescence quantum yield (QY) can be defined as the ratio of photons absorbed 
to photons emitted. It gives the probability of deactivation of the excited state by 
fluorescent emission only. Usually, QY is obtained by comparing test samples with 
standard samples having known QY values. The ratio of the integrated fluorescence 
intensities of the standard and test samples are obtained ensuring identical absorption 
at similar wavelengths (hence absorbance of same number of photons), and the QY 
calculated.  
 
Since up-conversion is a unique feature of lanthanide-doped luminescent materials, it 
is very difficult to find a standard solution with known up-conversion QY for 
purposes of comparison. Consequently, the up-conversion QY of the PEI/NaYF4 
nanocrystals are hard to determine and the literature is scanty and standards are absent. 
Hence, to obtain an objective measure of the upconversion process the emission 






for the different samples (Table 2-2).  
 
Table 2-2 Emission intensities under NIR excitation 
 
 NIR laser: set at 400 mW NIR laser: set at 200 mW 
PEI/NaYF4:Yb, Er 12~201  mW 4~10  mW 
PEI/NaYF4:Yb, Tm 5~9   mW 4~8   mW 
1X ~ Y indicates the range of data obtained during detection. 
 
 
2.3.2.3 Effect of prolonged laser excitation on emission 
 
To assess the rate of photobleaching, luminescence from PEI/ NaYF4:Yb3+,Er3+ 
nanoparticles deposited on a microscopic slide was measured over nearly 7 hours with 
continuous NIR excitation. The fluorescence peak fluctuated slightly within 4.1 ± 
8.8 % of original intensity and did not decrease (Figure 2-5). This suggested that the 
nanoparticles have high stability against photobleaching, and agrees with other reports 
showing similar results. The power of the incident laser beam usually has a significant 
bearing on the rate of photobleaching of a fluorescent sample. However, in this case, 
laser power was increased from a few micro-Joules/cm2 to the maximum possible 
recordable by the power meter. Further increase by focusing the beam with a convex 
lens resulted in powers high enough to saturate and damage the power meter. 
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Figure 2-5 Resistance to photo-bleaching 
2.3.2.4 Effect of prolonged storage on fluorescence emission  
 
Nanoparticles in suspension in PBS demonstrated little variation in peak emission 
over a period of almost 3 weeks (Figure 2-6). The particles were stored in ambient 
conditions without protection from light. In fact, stored particles showed almost no 
degradation in peak emission intensities even after 4 months after this experiment. 
Ability to store nanoparticles without loss in phosphorescence is very important not 
only for the ability for efficient use without waste but also for those experiments 
which depend on quantitative assays of fluorescence. The variation seen in the graphs 
stems mainly from the fact that the nanoparticles tend to settle on storage and need to 
be re-vortexed before testing. Another reason can be machine instability because of 
thermal fluctuations.  










































Figure 2-6 Storage stability. Upconverting nanoparticles were stored in PBS at room 
temperature and periodically observed for loss of emission. 
2.3.2.5 Effect of serum incubation at body temperature on emission 
 
The nanoparticles were incubated in DI water, DMEM and FBS for 15 days and the 
emission maxima measured at 0, 8, 12 and  15 days (Figure 2-10 A). DMEM 
(Dulbecco's Modified Eagle's Minimal Essential Medium), contains high amounts of 
amino acids, glucose and vitamins and several varieties of salts (potassium chloride, 
magnesium sulfate, sodium chloride etc). While there was no change on incubation in 
DI water, both DMEM and FBS caused a drop in emission to about 81% and 51% of 
the original values, respectively. The change in maxima was gradually progressive 



































Figure 2-7 Effect of incubation in different media at 37°C on emission from 
upconverting nanoparticles.  
 
 
The mechanism of upconversion fluorescence by non-radiative energy transfer within 
the dopant ions in the crystalline matrix is normally independent of environmental 
influences. Hence, the reduction in emission is probably not because of an alteration 
in the actual fluorescence process within the nano-crystal, but more likely due to a 
build-up of proteins on the surface of the nanoparticles, which impedes both 
excitation and emission radiations. Perhaps it is for this reason that smaller 
nanoparticles like QDs with sizes of the same order as large proteins, are more 
susceptible to this quenching (Figure 2-8). In the case of QDs, the comparable sizes of 
the particles (about 4-7nm) and serum proteins (variable, albumin ~7nm) argues 
against a similar notion of protein ‘deposition’ on nanoparticles. The mechanism of 
fluorescence loss for QDs have not been explained by the authors publishing those 


























on serum incubation 
 
Figure 2-8 Relative stability of emission after incubation in serum at 37°C measured 
as the time taken for 10% loss in peak emission of NaYF4, QD705, QD705 modified 
with RGD peptide and CdTe(CdSe) Type II NIR QD with oligomeric phosphine 
coating. 
 
It is known that serum proteins experience slow degradation over time on storage, and 
the rate of this degradation is directly dependent on the temperature at which serum is 
stored. This is mainly due to the larger energy available to the protein molecules at 
higher temperature which is manifested as faster Brownian motion and greater 
incidences of random uncoiling of the proteins. While in the human body this 
increased energy is necessary for rapid protein actions by structural alterations, but in 
storage it leads to random uncoiling and entanglement of erstwhile soluble globular 
proteins. If the observed reduction in emission is indeed due to protein deposition on 
the surface of the nanoparticles, then lower temperatures would greatly reduce this. 
 
Upconversion nanoparticles were incubated with FBS at 37°C, 4°C and -20°C 
(Figure 2-10Figure 2-9). Incubation with FBS at low temperatures appears not to 






mainly protein denaturation, which occurs rapidly at higher temperatures, that is 
responsible for the loss in emission.  
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Figure 2-9 Effect of serum incubation at low temperatures on UCN emission 
efficiency.  
 
Protein deposition with/without degradation from storage at higher temperatures 
appears to be the cause of the reduction in measurable emission observed. The 
degraded proteins are likely deposited on the surface of the nanoparticles, forming a 
protein ‘shell’ that obstructs passage of radiation. To determine the effect of deposited 
proteins, the nanoparticles incubated with FBS for 15 days were washed thrice in DI 
water, finally resuspended in 2 ml of DI water and the emission spectra obtained at 
980nm excitation (Figure 2-10).  
 
The slight increase observed after washing can be attributed to the change in media 
from the more opaque FBS to the clear and transparent DI water. Proteins can be 






serine protease that cleaves the peptide bond after residues with long, positively 
charged side chains like arginine and lysine. The smaller peptides thus formed can be 
washed away more easily.  
 



















Figure 2-10 Incubation with FBS at 37°C (A) but not at low temperatures (B) reduces 
emission with time. Emission is regained by washing and trypsinization (C). 
 
The washed nanoparticles were incubated with excess trypsin at 37°C for several 
hours. The particles were then washed free of trypsin and any peptide fragments, and 
finally resuspended in 2ml of DI water and spectra obtained. The maxima from the 
spectra regained the original values. Since the final media was DI water, the emission 
recorded was slightly higher than that of the original values obtained from the 
nanoparticles’ suspension in FBS. Since trypsinization and washing restored 
maximum values, it appears that the reduction in emission was due to deposition of 
protein on the surface of the nanoparticles.  
 






NIR excitation was upconverted to emission with red and green peaks. These peaks 
are exceptionally sharp and can possibly be used for multiplexed imaging. The 
emission is unaffected by continuous laser excitation over hours and storage at room 
temperature in PBS for weeks. However, the emission is reduced when incubated in 
serum at human body temperature. The reduction is likely due to protein deposition 
because serum has no effect at low temperature incubation and the emission is 
recovered if the nanoparticles are washed and trypsinized. The reduction is a limiting 







2.3.3 Cell viability test 
 
To evaluate the biocompatibility of the nanoparticles, human colonic adenocarcinoma 
HT-29 cells and human immortalized fibroblasts NIH-3T3 cells were plated in wells 
at about 104 cells/well. The cells were then incubated at 37°C for 6 hours with the 
medium containing different concentration of upconversion nanoparticles from 0.1 to 
0.4 mg ml-1. After incubation, the nanoparticles were washed out and the cell viability 
was determined using a MTT assay. The results show that the nanoparticles are not 
toxic to HT-29 cells or NIH-3T3 cells even at the relatively high concentration of 0.4 
mg ml-1. The 6 hour time period was chosen to allow sufficient uptake of the 
nanoparticles on the cell surface. 
 
 
























Figure 2-11 Biocompatibility with HT29 colon cancer cells. MTT assay of cell 
viability when incubated with NaYF4 nanoparticles (n = 4 wells for each data point, 







To determine how long exposure to nanoparticles affects cell viability, HT29 and 
NIH3T3 cells were plated in wells at about 104 cells/well and incubated at 37°C with 
upconversion nanoparticles for different time periods. The initial concentration of 
nanoparticles was 0.1 mg/ml. Media was changed in the wells every day to prevent 
accumulation of cell debris. The cell viability was measured with an MTT assay and 
compared to values from control wells incubated without nanoparticles for similar 
periods of time. The results showed that the cells were relatively immune to damage 
from upconversion nanoparticles even after long incubation periods. 
 
























Figure 2-12 Effect of time period of incubation. Human colon carcinoma cells (HT29) 
and fibroblasts (NIH3T3) were incubated with 0.1 mg/ml of upconversion 
nanoparticles for 2 weeks and viability measured as a percentage of control. (n=4, 
error bars represent SD) 
 
To compare the relative toxicity of QDs and UCN, green emitting commercially 
obtained QDs were incubated with HT29 cells at 0.1mg/ml and incubated under 
similar conditions as those stated above for UCN. At the different time points, the 






the control wells and the results expressed as percentages (Figure 2-13). It can be seen 
that the QDs caused higher cell death relative to the UCN. This effect gets more 
pronounced with longer periods of incubation. However, it is to be noted that the 
commercial QDs were CdTe(CdSe) with modified surfaces containing carboxylate 
groups. Organic polymer coating of the QDs would probably make them more 
biocompatible. 
 
























Figure 2-13 Comparative effect of UCN and QD on viability of HT29 cells 
 
A similar biocompatibility experiment with stem cells was performed by Dr Rufaihah, 
another member of our lab. Stem cell research has attracted a lot of interest and stem 
cells have been demonstrated to have a number of potential uses. However, the cells 
are very sensitive to the environment and an excellent method to demonstrate toxicity 
in a material. Bone marrow derived stem cells were treated with different 






period of incubation as well as concentration of the nanoparticles. The viability of 
non-treated cells is assumed to be 100%. The concentration used was the total molar 
concentration of sodium in the nanoparticle suspension as determined by the very 




Figure 2-14 Viability of bone marrow stem cells from rats after incubation with 
NaYF4/PEI nanoparticles with different concentrations for 1 day and 2 days. 
(Courtesy: Dr Rufaihah, CMBL, NUS) 
 
With the nanoparticle concentration of 1 µg/ml, incubation of the stem cells with the 
nanoparticles for 24 hours and 48 hours did not change the cell viability. When the 
nanoparticle concentration was increased to 25 µg/ml, the cell viability still remained 
above 90%. The nanoparticles appear to be safe when used in certain range of 
concentrations and within limited time periods of incubation. The UCN have showed 








Also important is the determination of their distribution in mammals after intravenous 
injection. This was carried out by Dr Rufaihah in our group using female Wistar rats 
weighing about 200 to 250g. The rats were anaesthetized and then injected 
intravenously with the upconversion nanoparticles at a concentration of 10µg/ml and 
were then euthanized at pre-determined time points; 0.5 hour, 24 hours and 7 days. 
The heart, lung, spleen, kidney, liver and blood were collected, weighed, incubated at 
37oC overnight in digestion buffer solution. Yttrium (Y) content in the samples were 
then determined using ICP-MS as a means of determining nanoparticle concentration. 
UCN had a rapid accumulation in lungs immediately after injection, but by 24 hours 
post-injection was already significantly reduced in all tissues with the highest 
concentration in the spleen. By 7 days the nanoparticles were undetectable 
everywhere except for a small amount left in the spleen. The reason for the high 
concentration of the nanoparticles in lungs is not known. However, a reasonable 
explanation is the lung capillaries act as the first filter in the vascular system. 
Injection of the UCN into the venous blood stream would take the particles initially to 
through progressively larger venous channels, until the particles reach the chambers 
of the heart. From there the particles would be ejected into the lungs and pass through 
smaller and smaller pulmonary arteries and arterioles until they reach the pulmonary 
capillaries where the speed would be the most sluggish. It is expected that this is why, 
after 30 minutes, the particles are found largely in the lungs where they are still 
navigating the capillaries.  
After 7 days, the particles are no longer found in the body tissues. Possible routes of 
excretion include skin, lungs and kidneys, with the latter the most likely candidate. 
Most nanoparticles are also excreted via urine, and it is reasonable to suppose that 













We reported the synthesis and biocompatibility of PEI/NaYF4 upconversion 
nanoparticles. Although PEI has been reported to be toxic for some bacterial cells and 
human hepatocytes, a very small amount of PEI is capped on the nanocrystal surface 
and thus the net concentration of PEI in the system is very low. The particles were 
demonstrated to be compatible with two different cell lines. Significant toxicity was 
























In this chapter, the PEI/NaYF4:Yb,Er upconversion nanoparticles described in the 
previous chapter were used to target and image live cancer cells. The upconversion 
nanoparticles, being coated with the polymer PEI, can be labeled with suitable ligands 
selective for cell surface molecules on cancer cells. For the following experiments, a 
folic acid – folate receptor interaction was used as a means of selectively targeting 
cancer cells. 
 
Several endothelial tumors (for example, derived from the ovaries, mammary glands, 
colon, lungs, prostate and brain) have been shown to possess elevated levels of folate 
receptors on their surface (Coney et al., 1991; Garin-Chesa et al., 1993; Holm et al., 
1991; Mattes et al., 1990; Ross et al., 1994; Toffoli et al., 1997; Weitman et al., 1994; 
Weitman et al., 1992; Weitman et al., 1992). Already, a large body of research has 
accumulated regarding the use of folic acid receptors as cancer targets. Since folic 
acid, the natural choice for ligand to the folic acid receptor, can be quite easily 
coupled to the nanoparticle surface, it has been used for targeting these to cancer cells.  
 
To determine to ability to use the upconversion nanoparticles as fluorescent biological 
probes, we therefore used folic acid as a targeting molecule to target the folate 
receptors on cells of HT-29 and OVCAR3 cell lines. HT-29 are human colonic adeno-
carcinoma and have been reported to carry overexpressed folate receptors (de 
Nonancourt-Didion et al., 2001). OVCAR3 is an ovarian cancer cell line that has been 







3.2 Materials and Methods 
 
3.2.1 Materials  
 
FA (approximately 98%), dimethyl sulfoxide (DMSO), N-hydroxy-succinimide 
(NHS), 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC), 3-
mercaptopropionic acid (3-MPA), boric acid and sodium azide (99.99+%) were 
purchased from Sigma-Aldrich. FITC-streptavidin was purchased from biomeda. 
Sodium chloride (NaCl) was purchased from LabScan. Polyethylenimine (PEI, 
branched polymer (−NHCH2CH2−)x(−N(CH2CH2NH2)CH2CH2−)y) of molecular 
weight 25kD, sodium chloride (NaCl, >= 99.0%), yttrium chloride hexahydrate 
(YCl3·6H2O, 99.99%), ytterbium oxide (Yb2O3, 99.99%), erbium oxide (Er2O3, 
99.99+%), ammonium fluoride (NH4F, 98+%), were purchased from Sigma-Aldrich.  
 
All of the reagents were used as received without further purification. PEI stock 
solution (5 wt%) was prepared by dissolving PEI in DI water. YCl3 and NaCl stock 
solutions (0.2 M) were prepared by dissolving YCl3·6H2O and NaCl respectively in 
DI water. YbCl3 and ErCl3 stock solutions (0.2 M) were prepared by dissolving 
corresponding oxides in hydrochloric acid. Cell lines were obtained and cultured as 
described in the previous chapter. 
 
3.2.2 Attachment of targeting ligand on upconversion nanoparticles  
 
A one-pot synthetic procedure was used to synthesize the PEI/NaYF4:Yb,Er 






centrifugation, washed several times with ethanol and DI water, and dried in vacuum 
at ambient temperature. To coat with folic acid, 8.4 µl of folic acid solution (0.01 mM) 
in DMSO was mixed with 3 ml of NHS (15 mM) and 3 ml of EDC (75 mM) in 
deionised water. 1 ml of PEI/NaYF4 nanoparticles (25 kDa, 1 mg/ml and 5 mg/ml) 
was added. The mixture was adjusted to pH 7 and shaken at 50 rpm overnight. The 
mixture was then centrifuged down at 6000 rpm and the residue was washed with 
deionised water. Centrifugation and washing were repeated twice, and the residue was 
stored in 2 ml of PBS.  
 
3.2.3 Size measurement with TEM 
 
Transmission electron microscopy (TEM) was used for direct determination of size of 
the nanoparticles after ligand attachment. The TEM measurements were carried out 
on a JEOL 2010 transmission electron microscope operating at an acceleration voltage 
of 200 kV. 
 
Sample preparation: A small drop of FA-PEI/NaYF4:Yb,Er nanoparticle solution in 
ethanol was put on a 50 Å thick carbon-coated copper grid (300 mesh). The excess 
solution was removed by gently touching the sides of the grid with laboratory grade 
filter papers. The samples were submitted for TEM photomicrography at the Electron 
Microscopy Unit at the National University of Singapore. 
 
3.2.4 Surface charge measurement 
 






salt solution, it is important to detect any change in surface charge brought about as a 
result of the attachment of the ligand to the surface of the nanoparticle. As described 
in the previous chapter, a Zetasizer (Malvern Instruments, UK) was used to quantify 
the zeta potential of the nanoparticles following the same sample preparation steps.  
 
3.2.5 Detection of aggregates in solution  
 
Similar to the procedure described in the previous chapter, the FA-decorated 
nanoparticles in solution were tested for presence of presence of aggregates using the 
NanosizerZS. The instrument uses dynamic light scattering to determine the relative 
abundance of particles/aggregates in solution. A bimodal distribution reflects the 
presence of aggregates. 
 
3.2.6 Detection of folic acid on the nanoparticles 
 
The presence of folic acid on the surface of the nanoparticles is necessary to target the 
folate receptors on cancer cells. Similar to the detection of presence of PEI on the 
surface of the upconversion nanoparticles, the very small amounts of FA on the 
particles’ surface require detection by the sensitive technique of Fourier transform 
infrared spectroscopy (FTIR).  
 
Sample preparation: Concentrated samples of the nanoparticles solution in alcohol 
were placed in an open glass petri dish and vacuum dried overnight. Two samples 
were used: one containing unmodified PEI/NaYF4:Yb,Er nanoparticles, and the other 






vacuum treatment were scraped off and mixed thoroughly with 0.15gm of potassium 
bromide (KBr) powder with a mortar and pestle. The mixture was compressed into 
pellets using a hand press and maintaining a pressure of 5000 psi for 10 minutes. Each 
pellet was loaded into the sample chamber on a Bio-Rad FTS156 spectrometer and 
the transmission spectra recorded. 400 readings were obtained for each sample and 
averaged to cancel out random noise. 
 
3.2.7 Incubation of nanoparticles with cancer cells 
 
HT29 and OVCAR3 cells were established in standard culture flasks using 
established procedures as detailed in the previous chapter. The day previous to the 
experiment, cells were subcultured into flasks, and about 10,000 cells of each were 
plated in the wells of a 24 well plate and grown overnight under 37°C and 5% CO2. 
The coverslips were then washed free of floating cells with PBS. The wells were 
observed under bright field and phase contrast imaging at a 20X magnification (total 
magnification 200X) using a Nikon binocular TE2000U inverted microscope. 
 
100µl of FA-PEI/NaYF4:Yb,Er nanoparticles (4.4 mg/ml) were added to the wells 
and the cells incubated for 1 hour at 37oC and 4% CO2. The cells were then washed 
thrice with PBS to remove un-bound nanoparticles.  
 
3.2.8 Confocal imaging 
 






nanoparticles (Fig 3-1). A 980nm NIR pumped diode laser was connected by a single 
mode NIR optical fibre to the Nikon binocular TE2000U inverted microscope with 
the help of engineers of EINST Technology. A special NIR water enhanced objective 
lens was used to obtain clearer pictures of the cells. The confocal output power was 
fixed at 500mW for all the experiments subsequently described. When using the 4x 
objective, with 980nm laser power output at 500mW, the actual power that is on the 
specimen lying on the culture dish is 150-200 uW (at any z position) as measured by a 
hand-held optical power meter (841-PE, Newport). 
 
The EZ-CII confocal program was used to set the parameters of the confocal scans. 
For most images a gain of 100-150 (usually 130) was used. A pixel dwell of about 55-
60 µsec was used. Only the green channel detector was used. The magnification lens 
had a magnification of 40X for a total magnification of 400X. All images were 
obtained in a specially darkened microscopy room to reduce ambient light. Bright 
field images and confocal images were superimposed using Adobe Photoshop with 
the only adjustments to the original images being in re-scaling for accurate overlap 








Figure 3-1 Schematic of the specially altered confocal microscope used for imaging of 
upconversion nanoparticles (the markings in red represent the changes from a 







3.2.9 Efficiency and specificity of targeting of nanoparticles to cancer cells 
 
To assess the specific binding of FA-coated PEI/NaYF4:Yb,Er nanoparticles to cancer 
cells, HT29 cells were incubated in a 24-well plate (TPP, Switzerland) (approximately 
80,000 cells/well) with 400 µl media at 37oC, 5% CO2 for 1 h. The media was 
removed and the cells were incubated for 1 h with 600 µl media and 100 µl FA-coated 
nanoparticles (0.5 mg/ml) in well column 1, 600 µl media and 100 µl uncoated 
nanoparticles (0.5 mg/ml) in well column 2, 500 µl media with 100 µl FA (0.01 mM) 
and 100 µl FA-coated nanoparticles (0.5 mg/ml) in well column 3, and 700µl media in 
well column 4. The cells were washed twice with PBS, extracted into 300 µl of 
DMSO and topped up to 1 ml using DI water. Fluorescence was measured with 
SpectroPro 2150i spectrophotometer (Roper Scientific Acton Research, MA) 
equipped with a 1200 g mm-1 grating and a 980 nm VA-II DPSS laser (current set at 
1.50 A). For quantification, the fluorescence peak in the region of 535-555 nm was 
plotted and expressed as a percentage of the fluorescence peak of 1 ml of uncoated 








3.3 Results  
 
PEI coated NaYF4:Yb,Er nanoparticles were synthesized using high molecular weight 
PEI as reported in the previous section. The PEI/NaYF4 nanoparticles were surface 
modified with folic acid (FA) through the EDAC-NHS reaction to covalently bond the 
carboxylate groups of FA to the amine groups of PEI. The pellet of washed 
nanoparticles after the binding reaction had a yellowish tinge in contrast to the white 
pellet of unmodified nanoparticles, probably because FA is yellowish to deep yellow 
in solution. The pellets were resuspended in PBS for further experiments. 
 
3.3.1 TEM of FA-PEI/NaYF4  
 
To determine the alteration in size after addition of folic acid, TEM images were 
obtained for the nanoparticles. FA-PEI/NaYF4:Yb,ER nanoparticles were about 55-
60nm in diameter, in contrast to about 50nm for FA-free nanoparticles.  
 







The average increase of about 10nm over unconjugated nanoparticles appears to be 
due to the layer of folic acid. However, because of the variation of diameters among 
individual particles, it was difficult to determine the increase with any accuracy. The 
final size of the FA–PEI/NaYF4 nanoparticles, about 60nm, is well within the 100nm 
limit which allows penetration of endothelial barrier. (Ferrari, 2005) 
 
3.3.2 Confirmation of folic acid binding on nanoparticles by FTIR 
 
FTIR was used to determine the presence of FA on nanoparticles after surface 
modification. In the figure below (Figure 3-3), the additional absorption peaks at 
around 1550 cm-1 and 2350 cm-1, were observed in the spectra of FA-coated 
nanoparticles but not in that of uncoated nanoparticles. These are probably the amide 
bonds that are formed between carboxyl groups of FA and amine group of PEI shell 
during surface modification.  































Figure 3-3 FTIR spectra from FA-PEI/NaYF4:Yb,Er (a) shows presence of the extra 







3.3.3 Alteration of zeta-potential due to folic acid attachment  
 
Zeta potential is an indicator of surface charge on the nanoparticles. The zeta potential 
of PEI/NaYF4:Yb,Er nanoparticles was determined to be positive (as described in the 
previous chapter), likely due to the profusion of amine groups on the surface. 
Attachment of folic acid resulted in an average zeta potential of: 
 
ζ = - 0.020 (average, n = 6) 
 
The value varied slightly in different samples, probably due to variable binding of the 
molecules. Thus binding of folic acid causes a change in the surface zeta potential of 
the nanoparticles. The negative zeta potential reflects the presence of folic acid with 
the negatively charged carboxylate group. The increase in absolute value of the 
surface charge from about 0.004 to 0.020 means that the nanoparticles have a greater 
tendency to stay in solution.  
 
3.3.4 Detection of aggregates by size distribution  
 
Dynamic light scattering was used to determine the distribution of sizes of 
nanoparticles in solution. The Zetasizer readings demonstrated unimodal size 
distribution, thus showing that modification of the nanoparticles’ surfaces with folic 









3.3.5 Imaging of cancer cells  
 
To demonstrate targeted live cell imaging, FA–PEI/NaYF4 nanoparticles were 
incubated at physiological conditions with human adenocarcinoma cells (HT29 cells), 
human ovarian carcinoma cells (OVCAR3 cells) and human breast cancer cells 
(MCF7 cells). The first two cell lines are known to express abnormally high levels of 
the folate receptors, while MCF7 cell line has very limited number of receptors. After 
incubation, the live cells were imaged in bright field and under NIR radiation using a 
confocal microscope equipped with a 980nm NIR laser. The laser output at source 
was set to 500mW.  
 
Reports from literature indicate that the number of folate receptors on the cells are in 
the order A>C>E (de Nonancourt-Didion et al., 2001), (Campbell et al., 1991). This 


















Figure 3-4 Phase contrast (A,C,E) and confocal (B,D,F) images of ovarian carcinoma 
cells (A,B), colon carcinoma cells (C,D) and breast cancer cells (E,F) incubated with 
FA-PEI/NaYF4:Yb,Er nanoparticles.  
 
Because biological samples do not possess upconversion properties, NIR wavelengths 
excite zero auto-fluorescence from standard samples. Therefore cells incubated 
without nanoparticles showed no fluorescence and hence zero background noise. It 
may be appreciated that the nanoparticles appear to be blurred and slightly out of 
focus. The fluorescence images actually have the same lens and focal distance 
adjustment as the bright field images. The impression of poor focusing is unique to 
the confocal imaging of phosphors with long wavelength light. The resolution of a 
confocal image varies inversely as the Point Spread Function (or Airy function): 
 
PSF = k.r.sin(θmax); 
where k = 2π/λ , λ = wavelength, θmax = angle made at the lens, smaller for higher 
magnification; 
 
Hence, the blurring is highest for higher magnification using long wavelength light 
illumination – conditions unique to upconversion phosphors. An appropriate PSF with 
a commercial de-convolution software algorithm can be used to reduce the 
fluorescence spread to single dots. However, in this research we have avoided all 






3.3.6 Effect of incubation period on uptake of nanoparticles  
 
UCN were incubated with HT29 cells and imaged with fluorescent confocal 
microscope over several days to determine uptake into the cells. Since the 
nanoparticles were targeted to surface receptors, it is not surprising that most of the 
particles are found to cluster on the surface of the cells.  
 
After 24 hours of incubation, (Fig 3-5 c) the fluorescence from the UCN can be seen 
as a halo surrounding the outline of the cells, However, after about 48 hours of 
incubation, the fluorescence can be seen from inside the cells. This means that some 
of the particles were internalized inside the cells. This is probably because of the 
internalization of the folic acid receptors themselves.  
 
The relatively large size of the nanoparticles (about 60 nm) is likely to be also part of 
the reason for the slow uptake of the nanoparticles. Another contributing factor can be 
the tendency to form aggregates on the surface of the cells, although such aggregates 










Figure 3-5 Uptake of FA-PEI/NaYF4:Yb,Er nanoparticles (0.1mg/ml, examples 
shown by red arrows) in HT29 colon cancer cells with different incubation time 








3.3.7 Upconversion nanoparticles as non-specific fluorescent labels  
 
Human colon adenocarcinoma HT29 cells were incubated with FA-coated and 
uncoated PEI/ NaYF4:Yb,Er nanoparticles. The binding of the nanoparticles to HT29 
cells was assessed from the fluorescence retained after washing the cells. A higher 
fluorescence was retained with FA-coated nanoparticles compared with uncoated 
nanoparticles (Figure 3-6). This may be because the FA-coated nanoparticles bind to a 
larger number of cancer cells specifically and more tightly. Uncoated nanoparticles 
demonstrated significant retention on the cells, most likely due to the formation of 
bonds between the positively charged PEI shell and negatively charged molecules on 
the cell surface or well surface.  
 
To determine if binding of FA coated nanoparticles was by FA receptors, excess pure 
FA was added. This resulted in competitive inhibition of FA/nanoparticles to the cells, 
resulting in a smaller number of nanoparticles attached to the cells, thus proving that 
the increased binding is due to receptor specific interaction (Figure 3-6).  
 
The high retention fraction of unmodified nanoparticles is a potential problem, but as 
long as the nanoparticles are conjugated to ligands, this non-specific binding is 
masked. However, the non-specific binding can be useful in some cases. For example, 
in co-cultures, two cell lines are mixed together to study their interaction. Confluent 
growth often makes it difficult to distinguish between the two cell types. Therefore, a 
non-toxic fluorescent label is required that can be imaged repeatedly without 
bleaching, and that has sharp emission lines to allow different dyes to be used together. 
To enable usage with any cell type, strong non-specific binding is an added advantage. 






































































Figure 3-6 Non-specific binding. Folic acid coated nanoparticles are retained more 
than uncoated nanoparticles by HT29 cells. This retention is antagonized by excess 
free folic acid in the medium. 
 
 
In a co-culture experiment, currently being conducted by a separate research group, 
osteoblasts and ligament cells from rabbits were used for co-culture with stem cells. 
To label the cells, a high concentration of PEI/NaYF4:Yb,Er nanoparticles were 
incubated with the cells overnight. After washing off the non-attached nanoparticles, 
confocal images revealed that a large amount of nanoparticles have attached to the 
cells, enabling easy detection in combined cultures (Figure 3-7). Therefore, the 
upconversion nanoparticles can be used for selective targeting by attaching a suitable 







   
 
Figure 3-7 Phase-contrast and confocal images of osteoblasts (A) and ligament cells 












In conclusion, we have reported the use of upconversion nanoparticles in the targeted 
imaging of cancer cells in vitro. Upconversion nanoparticles have several advantages: 
i) optical absorption coefficients of principal tissue chromophores in the human body 
show a very sharp ‘valley’ in the NIR region and hence allow deepest tissue 
penetration, ii) NIR light has low risk of photocytotoxicity, iii) the nanoparticles are 
themselves biocompatible and highly photostable, and iv) absence of upconversion in 
natural systems results in very high sensitivity. The simplicity of synthesis, 
universality of modification procedure and efficiency and stability of fluorescence 
means that these upconversion nanoparticles have great potential as a universal probe 
for imaging of cells and tissues for scientific and clinical use. Future work will focus 





















Use of reporter technologies in vivo is still in its infancy. For large structure 
visualization use of radio-opaque dyes with x-rays or use of ferro-magnetic fluids 
with MRI have had limited success. In recent years, there has been a growing interest 
in optical in vivo imaging systems because of the potential for repeated imaging 
without exposure to harmful ionizing radiations, acquisition of higher resolution 
images and because of the cheaper and smaller instrumentation involved. However, 
the requirements of and concerns about these techniques vary between clinicians, 
histopathologists and basic scientists. The major issues involved are safety and 
sensitivity. Clinicians and scientists working with live cells and organisms are 
concerned about the toxicity of the particles and radiation. Histopathologists, 
clinicians and scientists working with animal tissues have to consider masking of 
signal efficiency by autofluorescence from biological macromolecules like collagen 
and porphyrins (e.g. hemoglobin). It can be safely said that no single fluorophore has 
successfully addressed all the issues. 
 
For visual observation of in vivo structures and processes, fluorescent labels would 
require three important properties: low background and/or high signal efficiency, 
ability to be visualized at substantial tissue depths and stability of fluorescence in vivo 
over time. QDs and other fluorescent organic fluorophores generally absorb UV light 
and emit visible fluorescence. UV light has poor penetration efficiency in tissues and 
has moreover been known to promote certain types of cancer like melanoma. 
Moreover, UV light also excites strong fluorescence background from tissues. This 






Special QDs have been used and reported which absorb near infra-red radiation and 
emit infra-red radiations of higher wavelengths. Imaging is accomplished by special 
NIR detection cameras and the image is processed by appropriate software before 
presentation as false color images. This detracts from the usefulness of direct 
visualization and adds to the cost and complexity of the detection process. 
Nonetheless, NIR QDs have been used in vivo for: 
1. Imaging of tumor vasculature (Frangioni, 2003) 
2. Tracking of implanted cells (Voura et al., 2004) 
3. Sentinel node imaging (Soltesz et al., 2005) 
4. Neural imaging (Thorne et al., 2006) 
 
The search for an appropriate biological imaging probe has led to the use of up-
conversion phosphors. These materials absorb two or more photons of incident energy 
then non-radiatively transfer these photons between the excited species resulting in 
some ions attaining a still higher excitation state. These discharge the added energy as 
emission with higher wavelengths than absorbed radiation, the so called 
‘upconversion’ process. While this technology has been known for several decades 
now, the use of nanosized upconverting particles in biology is a relatively recent 
phenomenon. Since most biological tissues have minimal absorbance of NIR light, 
most such reporter labels have been constructed to absorb in the NIR range and emit 
in the visible range.  
 
Possibly the first use of these particles for in vivo use in live organisms was reported 
by imaging the phosphor particles in the nematode worm C. elegans. The authors 






from 50nm to 250 nm, thus in the process conforming to the widely accepted <100nm 
criteria that qualifies nanotechnology. However, some points regarding this study need 
to be noted. The study introduces the particles into the gastrointestinal tract of the 
worms by keeping the particles in the Petri dish. This method thus requires no specific 
surface modification of the particles and is not a true substitute for use in higher 
animals. While a range of sizes was synthesized, most of the results presented have 
been with particles of size >150nm. Thus the efficiency of sub 100nm particles for in 
vivo detection is unknown. 
 
In this chapter, the ability to use PEI/NaYF4:Yb,Er upconversion nanoparticles in 







4.2 Materials and Methods 
4.2.1 Materials 
 
Female Wistar rats about 200 to 250g were used for the first experiments. The mice 
strain C57BL/6 is the most widely used inbred strain and is commonly used as a 
general purpose strain. Female C57BL/6 mice, 4-6 weeks old were obtained from the 
Jackson Laboratory. All animals were used in compliance with the “Guide for the 
Care and Use of Laboratory Animals”, published by the National Institute of Health, 
USA and with ethical approval obtained from International Animal Care and Use 
Committee (IACUC), National University of Singapore. 
 
FA-PEI/NaYF4:Yb,Er upconversion nanoparticles were synthesized as described in 
the previous chapters. Green emitting (540nm peak) quantum dots with carboxylated 
surfaces were purchased from American Dye Sources, Inc (product ADS540QD).  
 
The laser set-up used standard laboratory equipment supplemented with a 980 nm 
VA-II diode pumped solid state (DPSS) laser (current set at 1.50 A). The imaging 
equipment was put in a darkened room and included a 980 nm VA-II DPSS laser 
(current set 1.0 A). This was recorded using CCD-based digital cameras with heat 
filters to eliminate NIR scatter. The depth of injection was estimated from needle 
penetration. Animal-to-laser distance was measured using a ruler attached to the laser 
head (Figure 4-1). For in vivo cellular imaging, the standard Nikon confocal 






   
 
Figure 4-1 Setup. A). The laser is held in position by a clamp. The power source 
(black box) is set at a output current of 1.5Amp. The ruler ensures that the animal skin 
is at the correct point for the focused laser beam. B) The anesthetized animal is placed 
under the laser such that the injected area lies in the laser path. 
 
4.2.2 Imaging of upconversion nanoparticles within rat skin 
 
The rats were anaesthetized with ketamine-xylazine mixure (ketamine 75mg/kg, 
xylazine 10mg/kg) by intraperitoneal injection and fur was clipped at the groin, back, 
abdominal and upper leg regions. 100 µl of PEI/NaYF4:Yb,Er nanoparticles (4.4 
mg/ml) was injected subcutaneously at these regions. At the end of the experiments, 
the animals were euthanized according to standard approved protocol. 
 
4.2.3 Comparison of upconversion nanoparticles with QDs for in vivo imaging 
 
Commercial green emitting quantum dots were compared to upconversion 
nanoparticles for in vivo imaging. After anesthesia, the skin on the back of the rat was 
shaved. Three areas were marked side-by-side on the shaved back with a black marker 







PEI/NaYF4:Yb,Er nanoparticles in PBS, the middle region was injected with 100µl of 
saline and the region closest to the tail was injected with 100µl of commercial QDs, 
used without further modifications. The rat was then imaged with NIR laser and UV 
light one after the other. Fluorescence from the injected area was recorded with a 
commercial CCD camera. 
 
4.2.4 Imaging of upconversion nanoparticles in other rat tissues 
 
Upconversion nanoparticles were injected into heart and muscle tissue to detect 
fluorescence in vivo from tissue depths. In case of the heart, to avoid the rib cage, it 
was dissected out and the nanoparticles injected into the muscular wall. Muscles in 
the groin region were injected with and without cutting and retracting the skin. 
 
4.2.5 In vivo microscopy using upconversion nanoparticles 
 
HT29 colon cancer cells were incubated for 1 hour with FA-coated UCN. The cells 
were washed free from excess nanoparticles, trypsinized and suspended in 1ml of 
PBS. Mice were anaesthetized with ketamine-xylazine mixure (ketamine 75mg/kg, 
xylazine 10mg/kg) by intraperitoneal injection and fur was clipped at the groin. The 
previously prepared cells were injected subcutaneously and the point of injection 
marked. The mice were placed on the stage of the Nikon binocular TE2000U inverted 
microscope connected to 980nm NIR pumped diode laser by a single mode NIR 
optical fibre. The point of injection was placed directly over the lens aperture. The 
lens aperture was guarded from soiling using two taped glass slides. Imaging was 






4-2). At the end of the experiments, the animals were euthanized according to 
standard approved protocol in compliance with the “Guide for the Care and Use of 








Figure 4-2 In vivo microscopy. A. Nikon binocular TE2000U inverted microscope 
connected by a single mode NIR optical fibre to the 980nm NIR pumped diode laser. 








4.3 Results and Discussion 
 
4.3.1 Imaging of subcutaneously injected upconversion nanoparticles  
 
Anaesthetized Wistar rats were prepared as described.in the previous section Different 
regions of the rat’s skin - back, abdomen and groin – were injected subcutaneously 
with 100 µl of 4.4 mg/ml of upconversion nanoparticles. The injection sites were 
marked and NIR laser at from a pumped diode laser at 1 Amp output current was 
focused there. A faint fluorescence can be seen with the naked eye at the injection site. 
The depth of injection was difficult to estimate because of the elastic nature of the 
skin but appears to be about 5-10 mm (Figure 4-3).  
 
Ambient light strongly reduced the observed fluorescence intensity. To improve the 
ability to image subcutaneous structures, better black box conditions than those used 
will be necessary. Another problem was with the image capture apparatus. Since 
ordinary CCD cameras were used, they tended to auto-compensate for the dark 
surroundings, resulting in a glare from the site of luminescence. This glare was 
worsened by the sensitivity of the CCD chip to infrared scatter from the laser focused 
at the site of injection. Use of special heat filters helped to reduce this. 
 
The experiments prove that the particles can be activated and the fluorescence 
obtained at small tissue depths. It remains to be seen if commercial UV-excited QDs 






     
 
 
Figure 4-3 Fluorescent emission on NIR laser excitation from subsutaneous injections 









4.3.2 Comparative imaging of subcutaneous injection of nanoparticles 
 
To compare with QD, 100 µl of commercially obtained green fluorescing QD was 
injected subcutaneously into a marked and shaved area over the rat abdomen. Similar 
volume of UCN was injected in a similar site for comparison and 100µl of PBS, 












In the square injected with UCN, luminescence was observed after using 980 nm VA-
II DPSS laser (current set 1.0 A) and was recorded using CCD-based digital cameras 
with heat filters to eliminate NIR scatter. However, the square injected subcutaneously 
with QDs did not show fluorescence under UV excitation. The square containing PBS 
did not show fluorescence under any conditions. The comparison provided here is not 
accurate and needs to be interpreted in the light of the differing conditions existing for 
the two particles. First of all, UCN need to be excited with a laser, while the QDs are 
excited with a portable UV lamp of lower power. Secondly, green emitting QDs have 
been used in this experiment. QDs emitting at longer wavelengths would be more 
suitable for such an experiment, like red emitting or even NIR emitting QDs. Finally, 
the depth of injection cannot be controlled accurately and would need to be 
standardized to make the comparison fair. What might be concluded here is that 
commonly used QDs, if excited under with standard laboratory lamps, usually cannot 
show fluorescence from under the animal skin. However, as some authors mentioned 
elsewhere in the thesis have shown, it is quite possible to view QD fluorescence in 
vivo under appropriate set-ups and choice of QDs.  
 
4.3.3 Imaging of injected nanoparticles in other tissues 
 
To test other tissues for detection of injected upconversion nanoparticles, UCN was 
injected into muscles and heart tissue. The luminescence intensity varied with the type 
of tissue injected, the muscles with skin removed showing a much stronger 
luminescence from deep injections than intact skin at similar depths. Luminescence 








Figure 4-5 Injection into other tissues in Wistar rats: A) muscle and B) heart showed 
detectable fluorescence. 
 
4.3.4 In vivo cell imaging  
 
HT29 colon cancer cells were tagged with FA-coated UCN. The cells were washed 
free from excess nanoparticles, trypsinized and suspended in 1ml of PBS. The tagged 
cells were injected subcutaneously in anaesthetized mice in the groin. The 
anaesthetized mouse was placed on the confocal stage with the site of injection placed 
on the light path. Since the microscope was inverted, the mouse was placed with the 
ventral surface (containing the injection site) facing downwards. It is naturally 
impossible to perform bright field microscopy in this position, but by marking the site 
of injection with a marker pen and careful positioning of the mouse, it was possible to 
place the point of injection on the path of light coming from the lenses below the 
stage. Adjustment of the z-focus was necessary to obtain the level of injected cells 
inside the mouse. 
 







large pinhole configuration of the confocal (to maximize light acquisition) the 
confocal image captures a thick slice of the tissue, and the cells have a ‘balls floating 
in space’ appearance, in contrast to the circular images of cell-slices in vitro (Figure 
4-6). In spite of the confocal slices being relatively very thick in the open pinhole 
configuration, the confocal microscope cannot be replaced by an ordinary 
fluorescence microscope for these experiments. Using an ordinary fluorescence 
microscope with limited power of adjusting focal depth, we could not see the 
fluorescence even from cell implanted just below the surface of the skin. 
 
In the obtained image, a fair amount of ‘free-floating’ nanoparticles can be seen. The 
clustering of these seems to suggest that they are derived from dead cells. It is not 
clear if this was present in the solution at the point of injection, or happened after 
injection even though the time interval between injection and obtaining of the images 
was less than an hour. 
 
There is a limitation to carrying out this kind of experiment for more than a couple of 
hours at most. The anaesthetized animal can ‘dry out’ in an air-conditioned laboratory 
environment without infusion of fluids, which is difficult on the kind of general set-up 
used in these experiments. More specialized equipment like heated stages will enable 









Figure 4-6 In vivo live cell imaging using NaYF4 nanoparticles. The ‘floating balls’ 
appearance of the cells in the bottom panel has a distinctive 3-dimensional quality 









In conclusion upconversion nanoparticle molecular imaging probes can potentially be 
used for in vivo cell tracking studies and diagnosis and monitoring for superficial 
tumors.  
 
In the clinical setting, these nanoparticles may find use in dermal or sub-dermal 
imaging and photodynamic therapy of pathologic conditions like melanomas, warts 
and burns, as well as for mucosal and sub-mucosal pathologies. Visual information 
regarding extent of the pathologic condition will be important for planning and 
performing surgical procedures. Attachment of photosensitizers to the upconversion 
nanoparticles makes it possible to do photodynamic therapy in deep tissues, because 
the upconversion nanoparticles can convert NIR light to visible light which can then 
activate the photosensitizers to release reactive oxygen species to kill pathogens.  
 
Along with therapeutics, monitoring of response to therapy can possibly be carried 
out without repeated exposure to radioactive chemicals and x-rays. Lastly, continuous 
live imaging of tissues in small animal models can be utilized in monitoring of tumors 
and exploration of pathologies without un-necessary sacrifice of animals. This is 










Chapter 5 UPCONVERSION NANOPARTICLES IN PHOTODYNAMIC 









Photodynamic therapy is a therapeutic option for cancer that relies on the interaction 
of light and drugs to kill targeted cells. Acceptance of PDT has been limited by fear of 
high cost of setup, comparative cure rates with conventional therapies, absence of 
standard protocols established by randomized trials, skin photosensitivity for 
prolonged periods and inability to easily reach deeper seated tumors. In this report we 
discuss the development of a ‘nano-transducer’ which can potentially address some of 
these problems.  
 
The nanodevice comprises of zinc phthalocyanine (ZnPC) photosensitizer bound to 
up-converting nanoparticles (UCN). UCN are composed of sodium yttrium fluoride 
(NaYF44) nanocrystals co-doped with the rare earth ions ytterbium (Yb
3+) and erbium 
(Er3+) with a polymeric coat of high molecular weight (25kD) poly(ethylene imine) 
(PEI). The photosensitizer ZnPC is adsorbed to the nanoparticles’ surface (Figure 5-1). 
 
PEI/NaYF4:Yb,Er nanoparticles when excited with 980nm NIR laser emit in the 
visible range with two relatively sharp peaks at 500-550nm (green light) and 650-
675nm. (Wang et al., 2006)The fluorescence excitation spectrum of ZnPC shows an 
excitation maximum at about 670nm and considerably overlaps the red emission peak 
for the upconverting nanoparticles. This overlap ensures that ZnPC in close proximity 
to the nanoparticles can absorb the emitted luminescent radiation when the 







To the best of our knowledge there has only been one earlier report of nanotransducer 
nanoparticles used for PDT (Zhang et al., 2007). Zhang et al used NaYF4 particles in 
size ranges from 60 nm to 120 nm which are then coated with a thin layer of silica 
incorporating merocyanine as a photosensitizer. Only the photodynamic therapy 
aspect of the nanoparticles was explored in the report qualitatively from the images of 
a single cell taking up indicator dye after 45 minutes of IR irradiation.  
 
In this work, we aim to use 50nm nanoparticles for a more detailed in vitro 
assessment of the photodynamic therapeutic potential, simultaneously demonstrate the 
use of these particles as cellular imaging probes, and explore activation of the 
particles in vivo in small animals.  
 
 











FA (approximately 98%), dimethyl sulfoxide (DMSO), N-hydroxy-succinimide 
(NHS), 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC), 3-
mercaptopropionic acid (3-MPA), zinc phthalocyanine boric acid and sodium azide 
(99.99+%) were purchased from Sigma-Aldrich. ADPA was purchased from 
Invitrogen. FITC-streptavidin was purchased from Biomeda. Sodium chloride (NaCl) 
was purchased from LabScan. Polyethylenimine (PEI, branched polymer 
(−NHCH2CH2−)x(−N(CH2CH2NH2)CH2CH2−)y) of molecular weight 25kD, 
sodium chloride (NaCl, >= 99.0%), yttrium chloride hexahydrate (YCl3•6H2O, 
99.99%), ytterbium oxide (Yb2O3, 99.99%), erbium oxide (Er2O3, 99.99+%), 
ammonium fluoride (NH4F, 98+%), were purchased from Sigma-Aldrich. All of the 
reagents were used as received without further purification. PEI stock solution (5 wt%) 
was prepared by dissolving PEI in DI water. YCl3 and NaCl stock solutions (0.2 M) 
were prepared by dissolving YCl3•6H2O and NaCl respectively in DI water. YbCl3 
and ErCl3 stock solutions (0.2 M) were prepared by dissolving corresponding oxides 
in hydrochloric acid.  
 
HT29 cells (human colon adenocarcinoma cells) and MCF7 cells (human breast 
cancer cells) were cultured in a media constituted of DMEM, FBS and antibiotics 
(streptomycin and penicillin) in a ratio of 100:10:1 in 75 cm2 flasks. The cells were 
incubated in a 100% humidified incubator with 5% CO2 at 37°C. The cells were 







5.2.2 Preparation of ZnPC standard curve by spectrophotometry 
 
2 ml of a 500nM solution of ZnPC in alcohol was taken in a cuvette and the emission 
spectrum from 550nm – 700nm for excitation at 400nm was recorded using a 
SpectroPro 2150i spectrophotometer (Roper Scientific Acton Research, MA). The 
solution was then diluted progressively and the process repeated. The area under the 
curve was used to plot the standard curve of fluorescent peak and concentration of 
ZnPC. Absorbance spectrophotmetry was performed on the 2ml sample of ZnPC to 
determine best overlap with upconversion fluorescence.  
 
5.2.3 Attaching ZnPC to FA-PEI/NaYF4:Yb,Er nanoparticles 
 
A one-pot synthetic procedure was used to synthesize the PEI/NaYF4:Yb,Er 
nanoparticles, as described previously. FA was attached to the surface as a targeting 
ligand using the EDAC-NHS reaction described earlier. 1 ml of ZnPC in alcohol 
(500nm) was added to 1 ml of 4.4 mg/ml FA-PEI/NaYF4 in alcohol and the mixture 
mildly shaken in an automated shaker for half an hour. The mixture was then 
centrifuged at 10,000rpm for 10 minutes to spin down the nanoparticles. The 
supernatant was carefully withdrawn and the particles re-suspended in deionized 
water. The washing process was repeated twice to remove unbound ZnPC.  
 
Unlike FA, ZnPC is adsorbed to the surface of PEI/NaYF4:Yb,Er nanoparticles rather 
than being covalently bound. This is because ZnPC, being highly non-polar, lacks the 






regions of the polymer PEI bind strongly to the non-polar ZnPC in polar solvents, 
preventing free dissociation. While in vitro leaching studies showed that ZnPC do not 
come out of the UCN in DI water or PBS, it was far more difficult to check if ZnPC 
does dissociate itself from UCN while in contact with cells. Centrifugation of the cells 
incubated with UCN at sufficient speed to spin down both cell and free floating UCN 
left a supernatant that was free of ZnPC. This seems to argue that even in the cellular 




Figure 5-2 Molecular structure of ZnPC and PEI. Non-polar ZnPC interacts strongly with non-







5.2.4 Detection of ZnPC on the surface of the nanoparticles  
 
FTIR was used to confirm the presence of ZnPC on the nanoparticles. Samples 
containing pure ZnPC, PEI/NaYF4 and ZnPC-PEI/ZnPC were dried in vacuum and 
finely ground with KBr and then pressed into pellets. Fourier transform infrared 
spectroscopy (FTIR) spectra were recorded on a Bio-Rad FTS156 spectrometer.  
 
5.2.5 Determination of singlet oxygen production 
 
Production of singlet oxygen was determined through the photobleaching of disodium, 
9, 10-anthracenedipropionic acid (ADPA). Since this molecular probe is destroyed by 
singlet oxygen species, the concentration of ADPA - as determined by absorbance at 
400nm - is inversely proportional to the effectiveness to energy transfer to molecular 
oxygen and has been used for different nanoparticle systems.(Wieder et al., 2006) A 
number of wells containing equal volumes of nanoparticles (4.4mg/ml) and ADPA 
(10µM) were prepared. Each well was exposed to laser excitation at 980nm for 
different time periods. As a control, wells containing similar amounts of ADPA and 
alcohol without nanoparticles were exposed to similar time periods of equivalent laser 
exposure. The concentration of ADPA remaining in the wells was read by measuring 
absorption at 400nm in a spectrophotometer. Care was taken to keep initial 
concentration of ADPA the same in all wells irrespective of laser exposure. Results 
were expressed as percentage of control sample containing no nanoparticles and not 








5.2.6 Targeted binding to human cancer cells 
 
HT29 cells were cultured on in wells of a 24 well plate for 24 hours. ZnPC-
PEI/NaYF4 nanoparticles (4.4 mg/ml) were added and the cells were incubated for 1 
hour at 37°C and 4% CO2, then washed thoroughly. Cells were imaged in bright field 
and under infrared excitation. The sample was excited with a specially fitted 
continuous wave infrared laser source and images captured in the bright field and 
confocal fluorescent modes. The images were combined using Adobe Photoshop to 
determine determination of distribution of the nanoparticles.  
 
5.2.7 Photoexposure of cells  
 
HT29 cells were plated in the wells of a 24-well plate at approximately 100,000 
cells/well. Different amounts of FA-ZnPc nanoparticles were added to the wells (0ul, 
50ul, 100ul, 150ul of 4.4mg/ml) then topped up to 300ul with media and the wells 
shaken for ½ hr at 37°C. The wells were washed free of unattached ZnPC-
nanoparticles, then exposed to 980nm laser for 5 minutes. The wells were then 
incubated at 37°C for another 2 days. 
 
5.2.8 MTT assay to check effectiveness of PDT 
 
To assess the effect of exposure to NIR laser on the cells with and without the 
nanoparticles, the cell viability was measured by MTT assay. Cells were cultured in 
for a further 48 hours after laser exposure. The media was removed and the wells 






topped up with 250ul media then incubated for 1 hr. Then all media was removed. 
After removing the medium, the wells are washed in PBS and intracellular formazan 
crystals were extracted into 300 µl of DMSO and quantified by measuring the 
absorbance of the cell lysate at 595 nm in a microplate reader. Cell viability was 
expressed as a percentage of the control. All results are averages ± SD of four samples. 
 
There is a possibility that the UCN act as no more than carriers of ZnPC and that the 
cell destruction is carried out because of a direct activation of the ZnPC by the NIR 
laser. While this is theoretically possible, the very low absorption of NIR light by the 
ZnPC (as seen by the absorption profile) seems to argue that this effect, even if 







5.3 Results and Discussion 
 
5.3.1 Standard curve for ZnPC 
 
The standard curve for ZnPC fluorescence was plotted as the area of the fluorescence 
emission spectrum (650nm - 700nm) versus known concentration of ZnPC in alcohol.  































Figure 5-3 Standard curve for ZnPC fluorescence emission. 
 
5.3.2. Encapsulation efficiency 
 
Using the standard curve, the encapsulation efficiency of the described method was 
determined to be approximately 97%. This is surprising since PEI is primarily a 
cationic polymer while ZnPC is highly non-polar. It seems likely that the ZnPC binds 
strongly either to the surface of highly non-polar nanocrystalline core wherever it is 






of carbon backbone without charged amine groups. High encapsulation efficiencies of 
ZnPC (80%) have also been demonstrated by others using PLGA 
nanoparticles.(Ricci-Junior et al., 2006)  




























Figure 5-4 Fluorescence emission spectra of PEI/NaYF4 nanoparticles with ZnPC 
attached and the supernatant after centrifuging the nanoparticles down. Attachment of 
ZnPC to the nanoparticles drastically reduces the amount of free ZnPC in solution. 
 
5.3.3 FTIR for presence of ZnPC 
 
FTIR was used to determine the presence of ZnPC on PEI/ NaYF4:Yb,Er 
nanoparticles after surface modification. In the figure below, the additional twin 
absorption peaks around 1450 cm-1 were observed in the spectra of ZnPC-adsorbed 
nanoparticles but not in that of uncoated nanoparticles. This suggests the presence of 




























Figure 5-5 FTIR spectra of ZnPC, PEI/NaYF4 nanoparticles and ZnPC-PEI/NaYF4 
nanoparticles.  
 
5.3.4 Spectroscopy to determine emission-excitation overlap 
 
PEI/NaYF4:Yb,Er nanoparticles when excited with 980nm NIR laser emit in the 
visible range with two relatively sharp peaks at 500-550nm (green light) and 650-
675nm (red light).(Feng et al., 2006) The fluorescence excitation spectrum of ZnPC 
shows an excitation maximum at about 670nm and considerably overlaps the red 
emission peak for the upconverting nanoparticles. This overlap ensures that ZnPC in 
close proximity to the nanoparticles can absorb the emitted luminescent radiation 
when the nanoparticles are excited with 980nm laser. To confirm this we excited the 
ZnPC-UCN complex with 980nm laser and attempted to detect characteristic 
fluorescence emission of ZnPC. However, the fluorescence emission spectrum of 
ZnPC peaks at 675nm for excitation at 654nm (emission peak of the UCN). Since 






evidence for ZnPC fluorescence in response to excitation at 980nm – which would 
show successful energy transfer from the nanoparticle to the photosensitizer – could 
not be unambiguously determined by this method.  
 
























 PEI/NaYF4 emission spectrum
 ZnPC excitation spectrum
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Figure 5-6 Emission spectra of PEI/NaYF4:Yb,Er nanoparticles when excited with 
980nm NIR laser (dashed line) overlaps considerably with fluorescence excitation 
spectra of ZnPC (solid line) ensuring efficient excitation. 
 
5.3.5 Singlet oxygen production by ADPA molecular probe  
 
Production of singlet oxygen on irradiation of the ZnPC-nanoparticle complex with 
980nm was determined through the photobleaching of disodium, 9, 10-
anthracenedipropionic acid). Since this molecular probe is destroyed by singlet 
oxygen species, the concentration of ADPA - as determined by absorbance at 400nm - 
is inversely proportional to the effectiveness to energy transfer to molecular oxygen 
and has been used for different nanoparticle systems.(Wieder et al., 2006) The ZnPC-
UCN suspension in PBS was irradiated with a 980 nm diode laser for different time 






nm demonstrated increased destruction of ADPA with time and hence the 
effectiveness of singlet oxygen production by the nanodevice on NIR excitation. A 
control sample containing only ADPA showed a marginal decline over time, probably 
due to photobleaching from the laser exposure. 
 






















Figure 5-7 ADPA destruction representing singlet oxygen production (measured by 
absorption intensity at 400nm) as a function of exposure time to NIR laser showing 







5.3.6 Targeted uptake of ZnPC-UCN by cancer cells 
 
Singlet oxygen species has a lifetime of less than 0.06µsec and hence a diffusion-limit 
in tissues of about 0.02µ. This makes it imperative that the nanoparticles be taken up 
by target cells. For more specific targeting to cancer cells, folic acid was covalently 
attached to the PEI using a standard EDAC/NHS reaction as previously 
described.(Feng et al., 2006) ZnPC was adsorbed to the FA coated particles. The 
ZnPC-FA-PEI/NaYF4:Yb,Er nanoparticles were incubated with human colonic 
adenocarcinoma cells (HT29 cell lines) and imaged by confocal microscopy at 
different time points. Although the nanoparticles rapidly clustered on the cell 
membrane bearing the receptors, uptake into the cells was slow with significant 
internalization requiring up to 48 hours of incubation at 37oC. The clustering appears 
to be specific for interaction with cell surfaces, since isolated clusters in cell free 
media are not seen, and DLS measurements show a single peak. 
 
Figure 5-8 Composite image of cells incubated with ZnPC-PEI/NaYF4 nanoparticles 








5.3.7 Effectiveness of PDT using ZnPC-UCN  
 
Effectiveness of this nanodevice in destruction of cancer cells was determined in 
vitro. HT29 cells were cultured according to standard protocols. About 104 cells were 
then transferred to each of 3 wells in a 6-well plate. One well was incubated with 
ZnPC-FA/PEI-NaYF4:Yb,Er nanoparticles, but not exposed to NIR laser, one was 
exposed to  5 minutes of NIR laser, but without any nanoparticles, while the test well 
contained nanoparticles and was exposed to the NIR laser. Phase contrast images of 
the wells were taken prior to the experiment. After 48 hours of incubation, the cells 
were washed and again observed under phase contrast microscope ( 
Figure 5-9).  
 
It was seen that significant number of cells in the test well had been killed. This 
destruction was patchy and apparently dependent on which part of the well was 












Figure 5-9 Photodynamic therapy with ZnPC-NaYF4. Phase contrast photographs of 
HT29 colon cancer cells taken at the start of the experiment (A, C, E) and after 48 
hours of incubation (B, D, F); incubation with the ZnPC-FA-PEI/NaYF4 
nanoparticles and irradiated with NIR laser (A, B), exposed to nanoparticles only (C, 













5.3.8 Effect of nanoparticle concentration 
 
After HT29 cells were plated in the wells of a 96-well plate, different concentration of 
ZnPC-nanoparticle complex added to the wells. Each well was irradiated with 980nm 
laser for 30 minutes and incubated for a further 24 hours. Cell viability was 
determined using standard MTT protocol. Cell viability was reduced for all 
concentrations incubated (average 43% for all concentrations), but for the amounts 
incubated, viability appeared not to depend on nanoparticle concentration.  
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Figure 5-10 MTT assay to demonstrate the phototoxic effect of the nanoparticles. 
Each well was exposed to 30 minutes of 980nm laser after incubation with different 










The use of photosensitizer-upconverting nanoparticle complexes as transducers of low 
energy light to toxic oxygen species has several advantages. Optical absorption 
coefficients of principal tissue chromophores in the human body show a very sharp 
‘valley’ in the NIR region and hence allow deepest tissue penetration. NIR light can 
penetrate depths an order of magnitude higher than visible light and can potentially be 
used for deeper structures. NIR light is also less harmful to cells and tissues and 
reduces the risk of inadvertent tissue destruction. Use of cheaper continuous wave 
diode lasers for upconversion (as opposed to expensive pulsed lasers for 2-photon 
PDT) reduces cost of setup and enhances cost-effectiveness of therapy. The use of 
laser rather than broad spectrum lamps has advantages and disadvantages. While laser 
gives exquisite control over the specific area of exposure, it also means that large 
areas cannot be illuminated simultaneously, thereby increasing duration of therapy. 
Although it remains to be proved, it seems reasonable to suppose that PDT systems 
that require NIR laser for activation will not be effectively excited by sunlight 
exposure. Side effects of skin photosensitivity will thus be reduced if not eliminated. 
This is also supported by rapid clearance of nanoparticles from the body: initial 
results from animal experiments appear to suggest that unmodified nanoparticles are 
cleared from circulation within 24 hours in the absence of tumors. Finally, 
nanoparticles have a natural tendency to concentrate in tumors due an enhanced 
permeation and retention effect contributed by disordered tissue architecture, 
increased vascularity, larger microvascular fenestrations and absence of lymphatics. 
This enables specific delivery of the nanodevice to tumors which can be enhanced by 






had been demonstrated that coating with folic acid promoted selectivity of binding to 
cancer cells over normal cells (e.g. fibroblasts). Hence, it can be reasonably assumed 
that the FA-ZnPC-UCN demonstrated here will also show selectivity towards cancer 
cells. 
 
In conclusion, we have described a nanodevice for cancer PDT where upconverting 
nanoparticles convert deeply penetrating NIR light to visible emissions, which are in 
turn used by the attached photosensitizer to convert molecular oxygen to toxic singlet 
species. It can be appreciated that this is essentially a platform technology with the 
scope to substitute ZnPC with other photosensitizers which absorb in the 540nm or 
650nm range. For example, tin etiopurpurin (SnET2) requires 660nm while tetra(m-
hydroxyphenyl)chlorine (mTHPC, Foscan) is excited at 652nm. Further studies into 














Fluorescent labels that are excited by the near infrared (NIR) radiation give rise to 
minimal autofluorescence because of lack of efficient endogenous absorbers in the 
NIR spectral range (Bremer et al., 2001; Konig, 2000; Larson et al., 2003) and the 
absence of upconversion among most biomolecules. This results in very high signal to 
background ratios. Photo-damage to cells and tissues is also greatly reduced because 
NIR is generally harmless to biomolecules in low doses. Penetration depths are 
increased several orders of magnitude (from a few mm for UV to up to as deep as 15 
cm in fibrofatty tissues like breast tissues for NIR). (Auzel, 2004; Soukka et al., 2005).  
The rare earth elements used in synthesis of upconversion nanoparticles have a lower 
toxicity than semiconductor elements of quantum dots. These chemically stable 
particles do not bleach and allow permanent excitation with simultaneous signal 
integration (Corstjens et al., 2005). Since upconversion occurs within the host crystal, 
optical properties are unaffected by the environment (e.g., chemicals, pH and 
temperature). Consequently, use of these particles is unaffected by the nature of the 
analyte in assays (such as whole blood, plasma, urine, sputum, or tissue homogenates) 
or by the microenvironment in cellular and subcellular imaging. UCNs typically have 
narrower absorption and line emission spectra, as compared to the downconverting 
fluorophores. The emission of upconverting particles consist of sharp lines 
characteristic of atomic transitions in a well-ordered matrix. To exploit these 
advantages, upconverting nanoparticles, or UCN, need to be developed and explored. 
 
For cancer cell targeting, folic acid was covalently conjugated to the PEI/NaYF4 
nanoparticles. The method of cross-linking FA to PEI involves a simple condensation 
reaction and the substitution of folic acid by other biomolecules such as antibodies or 






these experiments the human colonic adenocarcinoma cell line HT29 and the ovarian 
cancer cell line OVCAR3 were used because they possess high amounts of folate 
receptors on their surface. Live cells were imaged and the images showed the 
attachment of the upconversion nanoparticles onto the surface of the cells. While the 
binding of the nanoparticles to the surface of the cells is rapid and extensive 
fluorescence can be detected within an hour, uptake inside cells through the 
internalization of the bound receptor-nanoparticle complex is a much slower process 
and can usually be detected in significant amount only after 48 hours of incubation.  
 
However, using NIR to image cells has a disadvantage too. Since the maximum 
resolution achievable with microscope varies inversely with the wavelength of light 
used, using NIR imposes a theoretical limit on the quality of the achieved images. 
This can be seen in the fluorescent images obtained where small bright clusters of the 
UCN appear to be diffuse masses of nanoparticles. However, in the tradeoff between 
resolution and sensitivity, NIR presents reasonably high values of both. 
 
Uncoated nanoparticles are covered with a surface layer of PEI which is a highly 
positively charged molecule with a large number of amino groups. It is to be expected 
that these nanoparticles will be involved in formation of hydrogen bonds with 
negatively charged molecules on the surface of the cells and also on the free surface 
of the well plate. These nanoparticles thus show a moderately high non-specific 
binding to cell surfaces after incubation. Coating with folic acid, however, 
significantly lowers the amount of non-specific binding and spurious background 







However, much can be done to maximize the advantageous use of these nanoparticles 
in non-invasive live cell imaging. The simplicity of a one-pot synthesis and a 
universal binding mechanism for any carboxylate group containing ligand lends itself 
to ease of exploring variations of this theme. Substitutions with antibodies or peptides 
for more specific targeting can be a step ahead. The reduction of fluorescence 
degradation in biofluids can be utilized for long term imaging of cellular processes in 
vitro and in vivo. Addition of other molecules like drugs and biologic response 
modifiers to confer multi-functional nanodevices is an attractive field of exploration.  
 
The animal experiments were carried out using an imaging system equipped with a 
980nm laser and simple CCD cameras. Much can be done to improve this setup 
including mobile imaging platforms to record whole body scans of the animals. Better 
black-box arrangements can make possible significantly improved signal-to-noise 
ratios. Laser power can be optimized for maximal luminescence with minimal tissue 
damage although tissues do not have a strong absorption at the wavelength of 980nm. 
The scope and possible benefits of continuous imaging subcutaneous and muscular 
tissues in real time is immense and needs to be thoroughly explored. To the best of our 
knowledge, this represents the first study of imaging of live cells and deep tissues in 
animal using upconversion fluorescent nanoparticles. 
 
Photodynamic therapy of superficial and slightly deeper tumors is an exciting 
application for these nanoparticles. The next step, the testing of these nanoparticles in 
small animal model of tumor, has already started in our laboratory. We have started 
experiments on a bladder and skin tumor model for mice. It is an exciting area of 







In conclusion, UCN present an additional tool to the biologist working with 
fluorescent nanoparticles. However, in no way do these supplant existing fluorescent 
nanoparticles that have become popular with many biologists and researchers. One of 
the many reasons for that is the existing fluorescent nanoparticles are very much 
brighter than the UCN. For nearly all biological experiments, the most important properties of 
a fluorescent label are brightness and stability. Quantum dots have both qualities. Another 
advantage of commercially available fluorescent nanoparticles is the much smaller 
size than UCN. QDs are usually of the order of a few nanometers, usually less than 
10nm. This size being similar to that of the average protein molecule, QDs can be 
used in most biological experiments without hindrance. In contrast, UCN are several 
times in diameter to QDs and often less bright. While multicolor UCN have been 
demonstrated, QDs present a larger range of colors mainly because unlike UCN they 
can tuned by their size and not on the type of impurity.  
Having said all that, it is also to be noted that UCN are progressing towards being a 
mature technology, with more uniform particles of smaller diameter being reported 
every year. The main roles of UCN would not be replace QDs, but to present an 
alternative fluorescent label that has some specialized properties that can be profitably 
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